0 ABC-family_proteins_mediated_transport 0.41 4.67 3.34 5 1.69 7.24 4.78 3.58 9.62 4.64 7.05 1.45 2.81 8.27 9.61 4.91 9.95 9.42 
1 ABCA_transporters_in_lipid_homeostasis 8.27 4.36 3.91 6.04 9.02 1.53 2.92 3.82 4.21 7.16 7.18 8.95 4.47 7.26 7.71 5.38 8.69 9.12 
2 Mitochondrial_ABC_transporters 6.67 2.99 0.35 8.94 7.03 8.11 3.22 3.33 6.73 6.64 1.41 7.11 2.53 8.68 5.47 6.44 6.62 7.57 
3 Apoptotic_execution__phase 0.37 8.59 7.23 7.41 5.29 7.78 3.16 0.35 1.9 8.42 2.88 1.06 0.4 9.42 2.64 6.48 4.46 8.05 
4 Apoptosis_induced_DNA_fragmentation 8.9 7.29 3.7 3.5 0.06 1.01 3.93 5.48 6.29 6.23 0.84 9.54 7.56 8.4 9.66 3.76 9.31 3.08 
5 Apoptotic_cleavage_of_cellular_proteins 9.44 4.39 6.26 3.23 5.37 5.38 1.18 0.82 9.29 5.41 8.33 1.15 6.39 6.58 7.04 9.3 9.77 3.06 
6 Stimulation_of_the_cell_death_response_by_PAK-2p34 6.73 3.86 0.21 7.45 9.24 0.72 2.7 8.29 7.77 5.73 0.97 5.12 9.86 2.9 1.61 6.36 3.55 7.67 
7 Caspase-8_activation 6.55 5.74 0.31 0.52 3.5 1.5 9.41 7.24 9.66 4.3 1.07 1.91 0.07 3.37 4.57 2.87 7.53 3.83 
8 Death_Receptor__Signalling 9.45 9.09 2.09 7.58 2.21 5.88 4.22 9.46 5.06 0.3 4.13 1.68 9 5.91 7.62 6.55 4.1 3.59 
9 Regulation_by_c-FLIP 6.24 5.37 5.48 4.83 5.95 0.41 6.02 3.5 2.91 8.36 3.74 0.2 5.96 0.21 3.48 1.99 6.68 4.84 
10 Activation_and_oligomerization_of_BAK_protein 2.81 7.34 0.53 9.99 4.18 9.38 9 7.88 1.27 4.67 7.28 8.93 6.48 4.83 8.07 4.21 3.1 6.17 
11 Activation_of_BH3-only_proteins 8.13 5.14 3.09 6.16 9.35 4.51 6 2.49 5.19 5.56 7.98 3.03 2.24 0.08 8.44 6.09 9.89 7.02 
12 Activation,_myristolyation_of_BID_and_translocation_to_mitochondria 1.95 4.85 0.93 3.43 5.23 5.87 3.14 5.03 4.48 2 4.58 6.18 5.8 7.96 7.98 2.81 5.89 7.98 
13 Activation,_translocation_and_oligomerization_of_BAX 0.09 1.57 4.72 6.22 5.38 2.92 0.38 1.79 1.9 6.57 9.58 1.91 8.15 8.88 1.56 5.11 2.02 6.34 
14 Apoptotic_factor-mediated_response 2.72 0.55 3.28 6.46 3.62 8.86 8.75 4.33 8.69 1.42 8.44 4.16 8.81 9.98 3.22 6.51 0.21 6.99 
15 BH3-only_proteins_associate_with_and_inactivate_anti-apoptotic_BCL-2_members 5.57 4.76 8.92 3.89 0.75 7.12 6 5.1 0.03 8.69 8.61 6.88 4.01 7.89 2.55 4.23 0.02 5.85 
16 Permeabilization_of_mitochondria 1.82 2.85 0.88 4.26 6.17 7.57 8.32 9.32 1.69 1.54 7.21 1.89 9.76 3.29 3.68 6.92 4.25 5.55 
17 Release_of_apoptotic_factors_from_the_mitochondria 4.34 5.49 4.41 5.12 1.45 0.6 7.18 7.53 1.39 4.23 2.79 9.96 6.87 5.29 5.49 4.37 8.66 9.49 
18 Regulation_of_PAK-2p34_activity_by_PS-GAP/RHG10 1.93 1.95 2.97 4.16 2.86 1.05 4.88 2.82 4.55 7.34 1.14 7.01 3.16 6.71 7.86 2.63 3.13 3.55 
19 Regulation_of_activated_PAK-2p34_by_proteasome_mediated_degradation 1.85 0.53 9.12 8.08 8.32 9.45 3.13 7.56 3.21 5.58 6.46 9.82 4.81 1.44 1.96 2.22 1.29 1.61 
20 Role_of_DCC_in_regulating_apoptosis 5.35 4.5 1.73 4.66 0.44 6.59 2.92 4.39 2.53 0.24 1.54 5.1 7.45 6.49 1.86 3.13 4.74 0.22 
21 Passive_Transport_by_Aquaporins 1.68 0.18 7.87 9.05 9.58 3.91 2.02 6.25 4.77 4.14 3.14 8.24 3.34 8.74 3.72 1.59 8.33 0.7 
22 Regulation_of_Water_Balance_by_Renal_Aquaporins 4.87 2.97 5.18 1.77 7.73 2.7 7.63 6.68 1.92 9.85 1.02 4.8 2.13 6.27 8.02 0.99 5.27 6.25 
23 Transport_of_Glycerol_from_Adipocytes_to_the_Liver_by_Aquaporins 5.43 9.24 0.23 9.72 0.61 1.81 0.03 4.32 5.05 5.93 7.25 0.31 4.92 1.42 2.22 2.86 0.64 9 
24 Scavenging_by_Class_A_Receptors 1.87 3.6 4.13 9.74 2.7 1.7 2.35 8.33 7.11 7.6 8.96 6.67 2.85 5.5 1.4 6.94 6.95 6.24 
25 Scavenging_by_Class_B_Receptors 0.19 1.25 5.76 6.94 6.58 3.02 3.71 4.66 6.78 5.93 8.51 4.84 0.18 4.64 1.19 1.52 8 0.87 
26 Scavenging_by_Class_F_Receptors 0.6 9.26 0.1 7.57 1.7 3.15 5.76 2.27 0.43 7.58 1.64 1.09 8.82 0.86 5.65 4.87 5.77 4.74 
27 Scavenging_by_Class_H_Receptors 6.25 6.27 6.29 9.28 4.23 5.2 9.02 9.62 1.23 5.96 7.37 2.61 1.95 5.25 2.64 2.6 2.02 1.16 
28 Scavenging_of_Heme_from_Plasma 0.3 3.26 0.11 7.71 4.11 5.47 1.53 5.2 7.9 9.24 1.88 7.63 9.4 8.51 6.62 8.29 9 7.13 
29 G1/S_DNA_Damage_Checkpoints 9.58 5.78 3.65 0.07 4.77 2 0.58 4.39 3.03 7.6 3.57 3.24 4.77 1.08 1.13 8.87 8.01 8.5 
30 G2/M_Checkpoints 4.6 4.28 9.93 3.84 4.05 5.4 1.11 7.04 8.35 3.56 0.72 3.5 8.23 4.85 5.56 2.16 6.26 3.57 
31 Mitotic_Spindle_Checkpoint 5.26 3.57 3.37 2.71 8.69 3.61 8.96 0.22 6.17 1.12 7.17 6.96 5.85 0.41 4.23 1.29 2.29 5.65 
32 M_Phase 5.59 9.32 2.96 8.55 0.53 9.62 5.84 7.34 6.54 9.72 4.57 3.69 5.32 9.63 6.07 4.83 9.11 6.35 
33 M/G1_Transition 0.67 8.48 6.75 9.38 2.23 1.42 7.54 5.11 7.41 1.75 4.59 8.25 2.21 8.7 6.26 9.34 2.05 7.83 
34 Mitotic_G1-G1/S_phases 8.5 3.98 2.79 7.01 1.93 7.34 6.37 5.34 5.56 9.93 1.76 7.05 9.62 5.48 8.81 3 4.13 6.41 
35 Mitotic_G2-G2/M_phases 8.55 8.55 1.42 4.62 6.11 8.77 4.24 6.78 7.52 4.43 2.96 6.73 0.4 3.13 8.75 0.72 8.18 6.1 
36 Regulation_of_DNA_replication 0.17 9.32 1.12 6.95 1.69 8.31 0.4 4.88 6.85 0.9 4.97 5.89 9.9 1.45 3.53 3.14 6.51 7.4 
37 Regulation_of_mitotic_cell_cycle 0.44 2.58 3.35 7.59 1.92 6.05 2.64 1.81 5.03 8.29 7.75 6.08 2.92 9.97 5.49 5.56 5.61 6.27 
38 S_Phase 4.67 5.41 1.29 2.4 8.13 1.74 6.01 0.77 2.15 6.83 2.13 9.92 8.24 6.01 3.92 7.59 6.7 4.28 
39 Meiotic_Synapsis 0.27 0.84 0.75 7.86 4.98 9.7 2.87 8.47 6.04 5.03 2.21 6.63 7.06 3.63 0.1 1.71 4.89 2.4 
40 Nucleosome_assembly 1.64 5.42 6.19 9.13 5.91 7.04 8.18 2.32 7.5 2.05 9.75 5.39 3.03 4.22 0.98 2.47 5.84 6.48 
41 Telomere_Maintenance 9.71 8.64 9.13 0.75 5.45 7.12 5.46 6.78 7.69 2.62 5.19 9.85 2.89 9.44 8.65 5.4 2.45 5.08 
42 Cell-cell_junction_organization 3.18 8.7 6.01 3.23 1.32 4.72 1.52 0.87 5.7 7.63 9.01 1.03 4.23 5.27 6 9.69 0.15 5.65 
43 Cell-extracellular_matrix_interactions 0.28 5.43 3.47 0.88 9.43 6.37 4.09 4.63 0.49 6.81 5.88 3.42 6.08 0.6 2.21 7.58 9.54 8.88 
44 Type_I_hemidesmosome_assembly 1.46 6.9 9.49 8.43 4.3 6.2 7.48 0.67 5.36 7.83 0.35 2.26 1.85 0.38 8.53 6.29 2.24 7.48 
45 DSCAM_interactions 9.23 3.59 2.57 7.66 9.44 9.55 3.18 7.26 4.11 0.25 3.55 0.01 5.49 4.96 5.84 5.15 9.64 3.42 
46 Nephrin_interactions 0.75 9.13 1.42 1.96 9.48 0.72 4.26 6.06 1.73 4.29 4.04 7.05 6.26 8.12 3.75 0.93 5.65 0.36 
47 Signal_regulatory_protein_(SIRP)_family_interactions 7.36 1.41 8.14 9.94 2.56 6.52 9.36 8.38 4.82 3.55 0.15 1.31 2.3 8.41 6.25 0.11 6.37 1.86 
48 DNA_Damage/Telomere_Stress_Induced_Senescence 6.9 6.5 6.62 6.34 8.93 3.53 4.16 4.52 0.08 2.62 2.33 4.54 3.03 6.34 3.03 2.56 1.48 1.24 
49 Oncogene_Induced_Senescence 3.17 2.13 1.09 0.28 2 0.8 3.18 8.58 0.5 1.55 3.61 2.64 9.03 6.76 6.43 9.09 9.02 5.61 
50 Oxidative_Stress_Induced_Senescence 4.89 9.48 2.82 6.53 6.74 2.2 4.02 9.23 8.31 3.69 8.78 2.59 0.08 6.19 9.71 0.03 9.45 7.81 
51 Senescence-Associated_Secretory_Phenotype_(SASP) 5.04 3.92 6.85 3.13 6.98 5.89 7.22 9.38 0.37 4.1 4.61 2.34 5.08 9.61 9.59 4.93 5.15 2.69 
52 Regulation_of_Hypoxia-inducible_Factor_(HIF)_by_Oxygen 9.37 8.69 0.58 7 9.71 2.64 1.17 2.15 5.55 8.15 3.3 0.39 2.12 2.88 0.82 9.54 0.85 7.1 
53 Circadian_Clock 4.84 7.74 3.8 8.15 9.51 5.41 1.15 6.79 1.1 8.98 0.73 7.88 9.77 1.32 9.56 6.89 1.13 0.08 
54 BMAL1:CLOCK/NPAS2_Activates_Circadian_Expression 9.41 7.9 7.23 3.63 0.28 1.84 7.78 2 0.71 8.85 9.74 0.71 3.33 8.67 1.53 2.95 1.68 8.25 
55 Circadian_Repression_of_Expression_by_REV-ERBA 6.76 6.29 6.5 5.98 3.09 6.93 6.86 0.8 1.16 2.49 6.67 5.28 6.79 8.64 4.21 4.05 8.26 8.16 
56 RORA_Activates_Circadian_Expression 5.16 7.26 6.66 0.87 6.81 9.64 3.4 6.86 0.21 6.62 7.21 0.64 3.09 4.15 9.02 8.73 1.24 9.41 
57 Base-Excision_Repair,_AP_Site_Formation 7.45 7.62 4.23 5.31 8.06 2.68 3.18 6.02 9.07 3.07 4.81 0.12 1.36 6.3 1.14 8.09 0.84 5.56 
58 Resolution_of_Abasic_Sites_(AP_sites) 2.9 2.93 9.96 1.52 0.54 3.45 7.08 2.48 4.91 7.12 1.31 1.14 4.39 9.58 7.22 7.04 9.95 0.52 
59 Translesion_synthesis_by_DNA_polymerases_bypassing_lesion_on_DNA_template_ 2.69 4.79 2.38 4.23 9.18 8.66 6.59 4.98 4.86 1.96 4.62 6.33 1.58 0.22 1.46 3.92 0.37 9.25 
60 DNA_Damage_Reversal 6.47 4.58 6.02 8.07 0.98 8.3 2.92 6 2.78 7.99 3.52 4.48 8.82 5.4 3.15 5.75 7.62 5.67 
61 Reversal_of_Alkylation_Damage_By_DNA_Dioxygenases 3.36 3.97 4.18 8.97 8.28 8.51 8.16 2.3 4.49 9.25 6.58 2.29 5.2 9.4 5.6 1.47 1.62 6.55 
62 Homologous_Recombination_Repair 6.75 7.92 3.61 7.54 3.98 1.46 7.14 9.46 1.88 5.69 6.38 6.63 0.75 5.15 5.21 4.75 6.15 5.28 
63 Nonhomologous_End-joining_(NHEJ) 2.34 5.7 9.05 4.64 5.57 9.62 1.61 5.24 5.49 4.69 3.3 9.23 3.5 3.33 9.25 9.1 7.37 3.36 
64 Fanconi_Anemia_pathway 3.37 2.78 3.93 6.36 7.14 1.64 5.91 9.49 1.35 5.05 3.37 0.04 3.37 6.23 6.64 9.7 6.08 5.68 
65 Regulation_of_the_Fanconi_anemia_pathway 2.81 0.85 1.52 3.73 6.52 1.94 8.76 8.26 3.96 5.72 2.49 6.4 1.74 8.19 9.43 6.11 9.41 2.89 
66 Global_Genomic_NER_(GG-NER) 4.19 5.65 8.05 5.85 2.16 4.5 6.15 6.09 0.64 1.66 8.93 0.74 5.09 3 6.95 5.73 5.89 1.61 
67 Transcription-coupled_NER_(TC-NER) 1.72 9.68 3.58 0.31 2.68 4.26 5.1 4.22 7.74 7.79 9.1 5.52 1.82 3.91 4.95 7.64 8.74 3.64 
68 DNA_Replication_Pre-Initiation 9.02 2.55 4.6 4.74 9.72 8.21 1.22 5.47 5.77 7.89 6.05 1.95 5.94 9.5 3.43 7.54 4.81 0.12 
69 Association_of_licensing_factors_with_the_pre-replicative_complex 6.72 4.39 4.28 9.12 7.62 9.67 4.08 4.15 9.08 2.23 7.59 4.34 2.04 4.86 3.19 9.58 9.45 8.06 
70 Removal_of_licensing_factors_from_origins 1.66 7 3.67 6.92 7.87 5.32 5.56 9.74 4.47 0.21 2.83 2.22 3.31 3.76 5.83 9.48 7.23 9.82 
71 DNA_replication_initiation 0.18 7.76 2.2 1.11 1.82 8.56 4.9 9.25 3.24 4.86 6.77 9.69 6.43 5.34 6.77 6.68 0.68 9.91 
72 DNA_strand_elongation 1.96 7.83 8.28 7.27 4.26 8.71 6.97 6.12 7.03 0.27 4.08 5.45 5.08 1.85 2.38 2.37 4.43 3.13 
73 Switching_of_origins_to_a_post-replicative_state 5.01 8.5 1.28 1.11 6.5 1.49 1.92 4.54 8.69 6.81 4.65 2.67 7.13 7.93 6.34 4.72 9.72 8.3 
74 L1CAM_interactions 9.01 4.42 1.77 8.77 7.7 7.02 3.64 3.81 5.9 8.23 2.37 0.23 1.79 5.95 1.69 3.27 0.42 3.1 
75 NCAM_signaling_for_neurite_out-growth 1.82 0.58 9.26 4.87 6.7 5.28 6.51 2.58 2.13 8.6 7.83 2.86 7.42 6.1 4.72 1.28 4.34 8.41 
76 Netrin-1_signaling 7.18 5.03 8.67 8.65 9.38 8.81 2.57 7.5 6.14 5.98 4.58 6.61 0.63 7.56 8.07 2.78 4.89 4.35 
77 Semaphorin_interactions 3.65 0.75 5.86 3.86 8.33 3.6 3.3 0.48 9.28 4.92 4.33 8.4 7.66 7.35 8.1 5.99 8.37 8.92 
78 Signaling_by_Robo_receptor 9.82 3.28 3.52 3.69 2.44 7.94 6.08 2.52 6.47 4.32 5.35 2.08 2.64 4.97 2.43 6.49 0.15 8.41 
79 CDO_in_myogenesis 1.89 1 8.12 6.48 5.23 8.51 4.74 6.33 8.91 2 8.54 9.9 6.97 9.19 7.8 5.78 9.31 5.44 
80 Regulation_of_gene_expression_in_beta_cells 3.4 4.87 8.99 5.25 4.83 5.38 4.92 1.93 2.52 0.11 5.6 8.34 8.4 4.97 7.85 5.29 5.4 8.05 
81 Regulation_of_gene_expression_in_early_pancreatic_precursor_cells 7.91 3.92 2.1 5.49 5.78 9.79 9.71 2.77 0.73 1.93 6.2 4.97 8.26 2.76 7.9 5.82 5.78 1.59 
82 Regulation_of_gene_expression_in_endocrine-committed_(NEUROG3+)_progenitor_cells 4.18 4.89 1.59 4.49 9.24 0.72 3.8 0.08 9.67 2.08 4.77 5.03 3.7 6.07 1.96 0.74 7.22 6.11 
83 Regulation_of_gene_expression_in_late_stage_(branching_morphogenesis)_pancreatic_bud_precursor_cells 0.19 7.61 0.56 8.9 1.63 6.83 7.16 9.32 4.52 7.41 9.54 8.13 8.62 3.96 4.6 6.15 9.04 5.99 
84 Signaling_by_NODAL 1.36 6.8 1.98 0.32 3.87 5.84 2.4 5.17 0.06 6.7 2.41 8.82 2.49 5.23 7.58 1.05 6.21 0.95 
85 Regulation_of_Signaling_by_NODAL 2.96 9.16 6.78 1.78 5.79 0.58 5.77 7.5 0.07 7.29 0.81 9.95 6.78 6.76 7.53 8.99 7.84 5.65 
86 Transcriptional_Regulation_of_White_Adipocyte_Differentiation 0.93 6.08 1.72 2.43 9.29 5.14 1.68 0.55 1.91 9.73 9.22 7.48 6.51 9.86 1.44 4.46 5.77 5.17 
87 Abnormal_conversion_of_2-oxoglutarate_to_2-hydroxyglutarate 6.29 9.16 8.74 7.91 4.69 9.12 1.46 6.93 0.91 8.15 9.49 8.57 6.4 0.52 2.36 5.51 4.87 2.26 
88 Abnormal_metabolism_in_phenylketonuria 1.62 9.55 1.83 3.94 1.8 0.97 0.65 0.65 5.13 2.61 5.78 0.78 8.78 1.4 6.11 9.47 4.45 1.7 
89 Amyloids 9.75 4.89 7.5 1.49 3.33 8.65 2.14 2.82 0.07 4.32 8.96 3.67 5.22 8.82 8.1 6.41 2.31 1.87 
90 Botulinum_neurotoxicity 7.05 4.79 3.21 5.38 3.51 4.47 2.08 6.46 2.76 7.59 1.89 4.22 6.66 4.86 4.55 0.28 6.14 8.6 
91 Proteolytic_cleavage_of_SNARE_complex_proteins 2.53 7.77 3.48 5.03 8.61 4.31 0.82 4.55 1.97 1.06 7.52 8.21 2.96 2.81 0.21 4.55 9.47 1.24 
92 Translocation_of_BoNT_Light_chain 3.18 1.35 3.76 7.74 8.59 9.98 0.74 2.53 9.22 6.35 6.43 8.88 1.53 2.32 7.47 6.8 9.26 6.78 
93 Defects_in_biotin_(Btn)_metabolism 4.5 8.01 9.61 1.99 8.55 3.63 7.16 5.73 5.61 2.45 4.73 2.74 5.5 3.53 1.81 2.87 6.99 1.1 
94 Defects_in_cobalamin_(B12)_metabolism 6.43 4.65 1.72 5.29 9.81 1.12 4.76 3.81 2.47 8.9 6.71 8.05 3.72 0.32 9.89 3.2 1.65 4.31 
95 Retinoid_cycle_disease_events 6.58 2.93 2.06 5.78 9.48 2.06 1.71 1.66 3.96 6.97 0.2 6.94 5.29 7.88 1.09 9.84 9.69 9.78 
96 Visual_phototransduction 6.17 0.15 6.26 6.84 1.68 9.06 9.28 0.97 1.18 3.9 1.99 7.85 4.86 1.99 4.2 7.1 2.71 8.13 
97 HIV_Life_Cycle 4.15 0.85 3.18 5.8 3.31 2.67 3.87 4.44 1.86 5.07 3.6 8.27 0.74 4.31 1.52 2.71 2.68 6.93 
98 Host_Interactions_of_HIV_factors 8.85 3.37 3.11 6.04 6.77 4.06 7.68 0.22 4.13 0 5.42 5.37 0.38 3.88 3.55 2.89 6.47 1.81 
99 Host_Interactions_with_Influenza_Factors 0.93 5.84 9.87 7.61 4.93 2.17 5.01 4.82 4.47 6.65 7.53 1.04 0.84 0.95 5.25 2.21 9.64 7.81 
100 Influenza_Life_Cycle 8.72 1.06 6.56 3.43 5.93 0.8 0.8 8.68 4.11 7.13 9.68 2.51 2.16 0.79 7.68 0.4 5.31 9.33 
101 Phagosomal_maturation_(early_endosomal_stage) 7.79 6.63 2.59 6.53 9.36 0.95 3.65 8.74 7.2 8.35 6.8 9.76 4.55 7.25 0.71 8.08 5.59 1.56 
102 Response_of_Mtb_to_phagocytosis 6.02 8.32 9.05 4.4 3.75 5.62 8.85 9.62 0.8 8.36 7.97 2.02 5.08 0.8 3.4 0.76 0.58 4.93 
103 MPS_I_-_Hurler_syndrome 7.4 5.46 4.74 7.73 0.97 8.8 3.35 0.72 4 7.07 9.55 6.66 1.41 5.88 4.81 1.68 3.15 3.96 
104 MPS_II_-_Hunter_syndrome 2.25 0.09 0.12 1.36 4.55 7.62 0.43 7.42 0.21 9.22 5.12 2.48 0.18 3.68 7.17 7.14 6.5 2.9 
105 MPS_IIIA_-_Sanfilippo_syndrome_A 3.35 7.59 1.69 8.95 3.03 6.4 9.79 1.99 1.05 7.91 6.61 6.81 6.52 7.53 0.33 0.29 9.87 0.42 
106 MPS_IIIB_-_Sanfilippo_syndrome_B 2.53 0.83 4.2 8.14 7.18 2.44 0.63 2.29 6.52 8.64 7.69 4.7 0.05 0.47 5.94 4.87 3.26 2.76 
107 MPS_IIIC_-_Sanfilippo_syndrome_C 3.23 5.4 6.79 9.9 5.88 7.1 2.71 9.45 2.21 4.7 1.83 5.89 9.55 9.78 7.79 0.06 2.62 1.35 
108 MPS_IIID_-_Sanfilippo_syndrome_D 4.87 1.96 0.33 0.88 9.35 7.79 9.93 7.9 9.62 9.65 0.01 1.05 8.07 5.67 6.69 1.34 6.71 4.57 
109 MPS_IV_-_Morquio_syndrome_A 9.98 5.45 5.97 2.18 8.38 8.44 3.72 5.63 0.28 2.64 8.01 7.23 4.9 6.04 6.01 2.27 1.97 6.92 
110 MPS_IV_-_Morquio_syndrome_B 7.71 3.63 3.01 3.63 7.21 5.65 4.21 4.45 6.1 4.95 7.41 0.22 8.12 1.51 0.15 0.55 3.93 7.38 
111 MPS_IX_-_Natowicz_syndrome 2.79 8.82 6.08 6.54 8.22 7.07 2.45 3.38 1.44 2.9 3.39 1.54 6.04 6.23 2.25 0.78 7.24 9.81 
112 MPS_VI_-_Maroteaux-Lamy_syndrome 3.3 7.33 2.23 5.94 1.3 8.46 9.87 4.45 8.05 6.16 7.5 4.89 3.38 9.63 1.35 6.97 2.09 6.3 
113 MPS_VII_-_Sly_syndrome 2.24 9.08 7.37 4.74 9.2 3.72 2.93 8.55 7.34 5.61 0.56 6.06 1.84 0.75 3.82 1.19 7.41 4.32 
114 Constitutive_PI3K/AKT_Signaling_in_Cancer 6.84 7.79 2.79 2.83 6.67 8.36 1.25 1.18 7.37 0.28 1.19 5.77 7.37 0.91 5.56 7.95 0.6 9.01 
115 PIP3_activates_AKT_signaling 7.93 4.32 1.36 5.8 8.75 9.07 1.84 0.74 7.19 7.9 4.76 0.41 3.51 3.29 2.9 9.74 0.72 5.91 
116 Signaling_by_EGFR 1.89 7.87 4.9 2.39 8.93 0.53 0.63 6.81 9.03 0.05 1.76 4.79 6.95 1.39 4.68 9.98 0.83 6.39 
117 Signaling_by_constitutively_active_EGFR 5.15 6.21 9.93 8.26 7.22 8.38 8.28 5.81 3.99 9.78 8.91 0.23 9.43 8.34 2.43 3.49 7.02 7.07 
118 Signaling_by_FGFR 5.02 1.41 6.87 3.46 8.91 6.37 4.13 4 8.16 6.9 1.62 9.35 1.26 4.1 8.77 3.82 2.6 1.89 
119 Signaling_by_FGFR_mutants 7.05 8.74 6.63 7.22 1.95 5.66 3.6 0.38 5.88 8.11 2.45 4.67 4.25 8.67 1.89 5.42 0.63 5.47 
120 FBXW7_Mutants_and_NOTCH1_in_Cancer 5.02 6.17 0.99 0.23 2.26 2.03 0.48 0.51 5.7 6.36 4.58 9.67 4.56 4.05 5.31 9.62 8.19 9.75 
121 Signaling_by_NOTCH1_HD_Domain_Mutants_in_Cancer 5.56 5.31 4.95 0.44 5.91 8.03 3.88 9.15 4.5 3.19 2.72 7.91 3.83 1.33 7.75 6.42 5.69 3 
122 Signaling_by_NOTCH1_HD+PEST_Domain_Mutants_in_Cancer 9.54 0.78 5.85 2.57 3.33 8.93 4.9 1.03 7.5 2.33 7.22 2.71 6.11 9.9 3.38 6.41 2.58 0.47 
123 Signaling_by_NOTCH1_PEST_Domain_Mutants_in_Cancer 3.52 6.58 4.79 3.02 6.83 9.9 0.02 5.68 4.22 8.95 1.35 0.08 3.61 7.42 1.94 6.99 1.88 1.78 
124 Signaling_by_NOTCH1_t(7;9)(NOTCH1:M1580_K2555)_Translocation_Mutant 0.42 3.57 9.41 8.47 4.69 3.45 3.8 9.13 9.64 7.1 0.61 3.85 0.73 5.04 4.62 7.03 1.02 0.69 
125 Loss_of_Function_of_SMAD2/3_in_Cancer 1.54 5.29 5.52 0.74 1.49 7.3 2.44 8.44 0.49 1.18 0.65 3.63 5.52 7.73 4.7 7.31 7.47 5.11 
126 Loss_of_Function_of_SMAD4_in_Cancer 8.69 3.98 4.98 1.03 3.52 6.79 0.53 0.43 5.22 0.88 5.63 8.34 8.5 0.22 2.4 9.11 4.92 6.51 
127 Loss_of_Function_of_TGFBR1_in_Cancer 5.8 4.77 6.16 8.76 1.78 2.2 6.15 3.48 7.98 1.79 6.35 8.57 8.83 6.62 9.02 2.62 4.2 7.7 
128 Loss_of_Function_of_TGFBR2_in_Cancer 0.22 2.73 8.41 6.86 8.88 9.17 7.17 8.92 6.98 2.67 7.49 0.65 3.89 9.32 6.19 0.81 0.03 1.3 
129 Extracellular_matrix_organization 0.28 6.31 5.89 1.52 6.3 1.72 8.64 4.07 2.95 4.28 6.81 4.9 6.1 1.77 0.71 2.36 4.59 6.43 
130 Assembly_of_collagen_fibrils_and_other_multimeric_structures 8.4 6.33 0.37 8.93 6.3 2.74 9.93 7.82 2.03 4.61 2.9 6.62 3.07 9.97 1.51 4.23 8.9 7.17 
131 Collagen_biosynthesis_and_modifying_enzymes 6.4 7.03 5.66 8.83 6.61 6.59 2.45 3.86 6.51 7.65 6.01 8.4 2.09 4.97 2.83 2.5 0.58 4.21 
132 Degradation_of_the_extracellular_matrix 1.75 5.81 7.87 2.71 2.87 9.99 5.04 9.79 1.38 7 5.3 4.61 1.18 2.05 5.4 8.28 4.59 6.22 
133 Activation_of_Matrix_Metalloproteinases 3.98 7.6 0.98 9.35 4.81 6.14 5.67 4.93 5.96 1.61 7.46 5.38 6.7 5.38 4.76 5.55 9.17 3.71 
134 Collagen_degradation 7.6 7.52 7.58 4.33 2.55 0.65 7.26 4.01 0.34 7.59 3.93 5.48 2.73 7.92 1.93 9.33 1.37 1.03 
135 ECM_proteoglycans 6.9 2.11 6.94 6.68 6.27 4.98 9.89 2.48 8.79 6.47 1.49 9.31 6.69 8.75 5.98 4.49 4.36 5.99 
136 Elastic_fibre_formation 1.23 4.43 7.31 1.54 8.61 4.34 3.85 9.67 8.16 3.93 7.04 8.66 9.53 3.08 2.23 6.84 7.92 6.67 
137 Molecules_associated_with_elastic_fibres 0.48 4.69 9.3 8.11 8.14 0.9 4.27 7.43 6.04 5.99 4.74 1.95 5.06 1.58 5.89 8.58 8.09 8.89 
138 Fibronectin_matrix_formation 4.47 0.4 8.18 3.64 9.75 0.26 0.89 5.03 0.66 4.12 8.4 5.7 6.76 3.95 6.41 9.86 6.51 1.09 
139 Integrin_cell_surface_interactions 1.87 0.83 0.85 3.9 2.5 6.86 7.55 3.81 1.28 5.02 2.77 8.62 4.24 5.65 8.72 8.32 8.85 4.28 
140 Laminin_interactions 6.46 8.89 4.78 8.83 9.25 2.65 2.6 0.45 7.78 8.21 8.55 5.2 9.27 7.73 1.34 2.51 6.75 3.36 
141 Non-integrin_membrane-ECM_interactions 3.34 0.01 7.37 3.1 9.74 5.9 3.56 0.71 0.8 9.35 1.45 2.82 8.25 7.18 5.73 7.12 0.37 9.98 
142 Syndecan_interactions 9.05 1.62 7.17 6.92 5.39 0.47 9.46 1.03 2.31 1.15 8.39 8.58 8.29 6.45 3.94 1.99 6.45 2.72 
143 Binding_of_RNA_by_Insulin-like_Growth_Factor-2_mRNA_Binding_Proteins_(IGF2BPs/IMPs/VICKZs) 6.75 8.62 0.72 7.73 4.8 2.38 8.97 5.42 6.08 2.03 2.77 1.25 1.34 4.01 0.78 3.82 1.69 7.36 
144 Deadenylation_of_mRNA 4.78 9.39 1.38 7.21 4.26 6.63 6.77 5.75 7.24 9.81 7 9.61 8.62 0.02 4.48 0.95 6.84 0.16 
145 mRNA_Decay_by_3'_to_5'_Exoribonuclease 1.37 5.07 9.93 2.84 9.44 2.59 8.21 0.58 6.43 6.68 6.77 1.19 8.57 0.41 8.91 2.64 6.23 9.15 
146 mRNA_Decay_by_5'_to_3'_Exoribonuclease 0.72 9.29 8.41 7.15 6.15 5.36 9.57 7.59 7 4.52 0.93 2.41 8.29 4.48 2.27 7.98 2.24 3.24 
147 Generic_Transcription_Pathway 2.74 1.33 8.85 0.38 1.7 8.62 6.29 0.84 9.09 8.78 9.23 0.85 4 0.24 1.93 1.05 4.12 7.65 
148 Notch-HLH_transcription_pathway 7.67 4.07 6.77 7.84 7.04 7.9 8.34 8.91 6.21 0.85 7.34 1.9 5.42 9.98 0.86 0.18 6.21 4.24 
149 Nuclear_Receptor_transcription_pathway 5.97 3.76 2.54 6.69 1.08 9.27 4.93 0.68 3.66 1.02 4.38 6 8.19 3.18 2.9 9.84 3.39 5.56 
150 Transcriptional_activity_of_SMAD2/SMAD3:SMAD4_heterotrimer 8.08 6.32 4.78 8.14 7.87 2.39 0.74 0.2 8.27 5.54 9.88 4.41 7.98 6.42 0.02 3.21 1.04 9.46 
151 YAP1-_and_WWTR1_(TAZ)-stimulated_gene_expression 0.56 5.09 8.33 7.08 7.61 5.33 6.86 8.04 3.85 1.42 8.42 2.6 1.61 6.2 3.43 5.78 1.87 1.13 
152 snRNP_Assembly 0.63 5.91 9.34 4.15 6.56 7.61 0.12 4.11 9.59 2.51 7.38 3.7 1.24 5.07 0.07 5.84 9.51 1.01 
153 Nonsense_Mediated_Decay_Enhanced_by_the_Exon_Junction_Complex 4.89 9.58 4.41 7.9 0.13 4.12 8.55 0.6 0.93 4.72 4.02 6.76 5.43 3.73 2.66 6.51 2.75 5.28 
154 Nonsense_Mediated_Decay_Independent_of_the_Exon_Junction_Complex 5.32 7.61 4.69 5.03 7.29 1.07 8.92 4.51 9.53 3.92 5.7 5.19 4.72 4.07 4.94 5.05 4.4 3.83 
155 Processing_of_Capped_Intron-Containing_Pre-mRNA 2.62 4.09 6.07 0.38 3.6 4.71 1.71 6.54 9.47 5.14 5.23 2.29 4.89 7.66 8.87 7.56 6.32 4.7 
156 Transport_of_Mature_Transcript_to_Cytoplasm 7.39 6.66 5.22 2.83 1.6 5.53 7.05 0.91 2.59 3.86 6.87 6.29 0.42 3.17 0.45 3.56 3.88 4.52 
157 mRNA_3'-end_processing 1.54 4.66 8.33 7.6 9.19 6.31 7.38 2.67 7.76 0.98 3.14 3.2 0.53 0.07 4.69 2.16 7.22 8.42 
158 mRNA_Splicing 0.07 4.63 2.6 9.47 7.93 6.3 7.17 0.43 3.76 3.14 6.26 1.17 3.34 6.2 1.71 7.92 9.64 1.54 
159 Processing_of_Intronless_Pre-mRNAs 8.66 6.93 6.64 7.75 0 2.12 1 5.51 4.76 3.79 9.43 8.77 7.89 3.61 3.85 2.72 4.34 1.44 
160 SLBP_Dependent_Processing_of_Replication-Dependent_Histone_Pre-mRNAs 5.61 5.63 5.04 9.46 8.88 3.08 1.57 4.3 1.23 4.64 0.74 3.46 8.37 9.81 3.18 6.11 2.92 5.91 
161 SLBP_independent_Processing_of_Histone_Pre-mRNAs 8.32 1.23 4.61 9.91 4.61 3.3 4.98 3.69 2.91 4 1.79 1.17 3.17 9.14 5.95 4.41 9.36 8.67 
162 RNA_Polymerase_I_Transcription 0.28 4.53 9.09 9.73 9.81 5.03 5.69 8.16 8.83 3.67 3.85 4.02 2.3 1.57 6.81 5.67 3.1 8.66 
163 RNA_Polymerase_III_Transcription 6.87 1.71 4.77 2.45 7.64 2.38 6.71 0.47 1.15 5.92 3.11 6.57 4.05 0.53 1.71 5.8 7.4 5.3 
164 Transcription_from_mitochondrial_promoters 6.75 3.2 7.9 3.77 9.98 5.86 6.04 4.89 6.31 7.44 3.88 6.1 7.18 9.19 2.59 9.27 6.09 1.19 
165 RNA_Pol_II_CTD_phosphorylation_and_interaction_with_CE 4.79 7.16 3 3.96 8.53 4.58 8.3 5.93 8.06 8.49 8.54 2.72 1.6 2.94 0.54 3.33 1.46 2.29 
166 RNA_Polymerase_II_Pre-transcription_Events 4.71 4.28 5.59 2.41 4.21 6.88 3.66 0.33 6.85 2.7 3.29 2.61 8.6 2.08 9.82 1.62 5.06 8.78 
167 RNA_Polymerase_II_Transcription_Elongation 9.79 8.97 8.87 5.38 4.69 7.83 5.4 7.95 2.66 6.33 5.09 5.57 3.17 1.34 0.53 1.35 2.58 5.93 
168 RNA_Polymerase_II_Transcription_Initiation_And_Promoter_Clearance 8.43 6.93 4.66 9.51 1.4 0.94 9.37 1.74 5.12 0.97 5.51 6.95 8.17 4.92 2.92 2.37 5.3 6.13 
169 RNA_Polymerase_II_Transcription_Pre-Initiation_And_Promoter_Opening 2.96 7.1 3.89 6.28 8.09 7.86 7.44 8.4 1.82 5.69 1.2 3.93 2.92 9.62 2.14 5.27 8.07 1.94 
170 RNA_Polymerase_II_Transcription_Termination 7.05 7.13 0.11 9.13 6.93 6.64 2.03 9.95 7.62 3.81 9.46 9.09 0.48 7.68 6.24 5.11 9.54 2.35 
171 Destabilization_of_mRNA_by_AUF1_(hnRNP_D0) 1.27 6.33 2.4 8.62 1.27 5.77 8.17 3.4 1.42 1 4 5.58 4.76 1.54 9.35 4.3 8.31 2.95 
172 Destabilization_of_mRNA_by_Butyrate_Response_Factor_1_(BRF1) 5.37 6.23 9.22 9.27 0.29 2.11 2.11 7.54 8.8 2.53 2.93 3.21 7.85 5.28 4.43 0 5.55 6.71 
173 Destabilization_of_mRNA_by_KSRP 2.7 4.52 3.75 6.31 6.4 9.34 0.4 9.86 8.34 2.48 5.39 7.65 7.96 3.12 2.62 0.52 7.31 9.87 
174 Destabilization_of_mRNA_by_Tristetraprolin_(TTP) 4.64 5.57 2.48 5.56 1.7 4.5 1.82 3.01 2.93 0.99 3.32 0.44 3.31 0.75 0.04 0.5 0.26 0.66 
175 Stabilization_of_mRNA_by_HuR 7.38 8.01 6.23 8.43 4.41 3.8 6.95 9.18 6.59 3.63 6.28 3.29 0.88 8.54 6.13 9.79 5.69 6.66 
176 MicroRNA_(miRNA)_Biogenesis 6.79 5.77 8.37 4.02 1.15 2.92 7.23 8.72 4.48 3.23 1.53 9.48 3.95 1.97 5.08 9.08 4.11 9.93 
177 Post-transcriptional_Silencing_By_Small_RNAs 6.65 7.81 2.02 6.1 8.28 2.56 7.05 9.65 0.23 7.69 7.15 2.53 8.05 6.84 4.78 1.45 8.4 8.33 
178 Small_Interfering_RNA_(siRNA)_Biogenesis 2.85 9 9.68 9.94 6.33 8.85 3.48 2.81 0.32 2.56 9.1 8.72 9.82 9.01 3.06 6.35 8.6 4.71 
179 Eukaryotic_Translation_Elongation 5.27 1.37 3.43 7.68 2.33 9.95 1.71 6.03 9.42 0.11 8.79 0.34 5.12 5.93 5.3 1.61 2.34 2.58 
180 Eukaryotic_Translation_Initiation 9.26 9.06 1.91 4.43 1.88 2.27 7.19 4.84 2.24 0.93 4.35 2.24 0.94 5.82 8.67 6.27 0.05 1.46 
181 Eukaryotic_Translation_Termination 6.86 5.89 5.4 2.37 8.5 7.59 5.78 9.56 6.77 4.03 0.42 3 8.11 2.25 1.43 5.95 0.16 6.15 
182 SRP-dependent_cotranslational_protein_targeting_to_membrane 8.04 0.06 3.68 6.41 3.35 6.98 3.25 3.13 0.23 3.12 6.18 4.57 3.96 3.39 0.86 0.94 8.46 0.43 
183 mRNA_Capping 5.22 9.11 2.8 4.55 3.58 8.47 8.7 9.9 8.73 3.27 4.13 4.54 8.96 4.72 4.5 2.41 6.41 6.46 
184 mRNA_Editing:_A_to_I_Conversion 5.25 2.13 8.24 9.29 6.95 4.03 5.94 9.93 0.67 1.87 6.4 0.79 0.41 1.25 5.34 8.6 0 9.07 
185 mRNA_Editing:_C_to_U_Conversion 6.21 6.92 2.93 1.17 7.17 4.03 9.43 8.93 6.39 0.11 9.25 0.28 9.78 7.48 8.5 8.92 4.44 6.54 
186 Cytosolic_tRNA_aminoacylation 6.23 3.53 0.36 5.47 3.46 8.26 0.61 9.04 2.38 5.71 8.86 4.05 2.99 0.56 7.28 2.67 7.51 0.19 
187 Mitochondrial_tRNA_aminoacylation 9.91 1.66 7.17 8.46 0.93 1.87 4.21 9.12 8.67 2.99 4.44 8.97 2.01 3.28 9.42 1.04 7.68 7.68 
188 Cell_surface_interactions_at_the_vascular_wall 6.41 2.96 2.62 7.2 2.44 9.18 6.25 2.19 5.84 1.74 9.84 4.59 1.49 0.14 6.95 5.03 0.32 8.51 
189 Basigin_interactions 5.37 8.14 3.63 6.51 2.19 2.9 9.17 6.83 9.18 5.84 2.52 5.86 2.69 2.48 1.37 3.97 4.24 1.68 
190 PECAM1_interactions 0.27 1.48 9.93 3.82 2.71 6.69 8.93 8.77 0.14 1.04 4.84 9.43 4.95 8.11 2.93 8.92 7.98 9.9 
191 Tie2_Signaling 2.99 8.9 4.93 0.74 5.49 7.74 3.14 1.73 0.69 2.18 8.65 8.33 2.38 9.11 2.52 4.63 5.08 1.49 
192 Dissolution_of_Fibrin_Clot 0.88 2.45 2.31 9.2 1.06 2.71 3.68 4.21 2.58 1.57 6.47 9.82 2.38 1.22 7.23 9.06 7.06 1.89 
193 Factors_involved_in_megakaryocyte_development_and_platelet_production 1.56 3.45 3.51 9.23 1.18 5.5 0.97 8.36 5.91 4.06 5.1 8.13 6.51 8.8 8.44 7.43 7.41 2.45 
194 Kinesins 5.78 9.49 7.05 5.14 7.85 2.27 6.24 2.04 3.56 9.17 2.27 5.55 1.02 2.86 4.68 6.98 9.79 4.11 
195 Common_Pathway 4.89 7.58 4.9 7.75 4.1 1.32 0.89 2.96 9.5 1.12 1.22 5.29 6.72 8.36 2.77 5.53 9.76 6.7 
196 Extrinsic_Pathway 0.85 6.52 7.51 3.97 7.51 0.01 4.35 6.93 0.72 9.16 7.16 3.28 5.11 1.25 8.38 2.96 9.39 5.44 
197 Intrinsic_Pathway 0.56 8.26 9.02 7.58 5.88 0.21 5.86 1.08 7.77 6.28 9.79 9.47 5.49 2.8 2.45 1.28 0.62 4.26 
198 Platelet_Adhesion_to_exposed_collagen 7.19 6.77 0.91 0.47 7.85 2.31 4.06 6.84 9.54 7.69 7.09 9.56 4.21 9.45 4.65 0.16 8.6 4.97 
199 Effects_of_PIP2_hydrolysis 3.35 1.9 6.77 0.49 0.05 8.86 3.88 6.75 1.43 3.77 1.3 4.87 5.55 4.82 2.53 0 7.54 2.89 
200 GP1b-IX-V_activation_signalling 4.88 2.15 0.08 3.1 9.4 7.99 9.97 7.07 4.54 3.04 2.37 4.85 4.99 7.92 6.13 6.12 6.82 9.83 
201 GPVI-mediated_activation_cascade 3.51 1.29 1.37 0.33 6 8.64 6.83 8.57 9.68 7.1 9.68 7.08 6.41 7.32 4.37 6.84 4.99 7.01 
202 Platelet_Aggregation_(Plug_Formation) 8.69 5.83 2.56 6.92 6.4 0.87 0.12 8.1 8.2 8.35 6.63 6.15 8.97 6.77 7.74 1.34 5.53 5.33 
203 Response_to_elevated_platelet_cytosolic_Ca2+ 8.78 2.86 6.24 7.34 0.75 3.49 7.12 9.84 6.24 7.92 5.04 8.22 0.55 9.13 4.62 4.73 0.84 1.6 
204 Signal_amplification 1.22 0.53 3.97 8.22 7.5 3.37 9.17 0.06 9.31 1.97 5.05 2.36 3.57 5.99 2.9 8.98 9.85 4.47 
205 Thrombin_signalling_through_proteinase_activated_receptors_(PARs) 0.84 5.92 7.25 9.96 8.55 8.28 3.38 3.42 4.28 7.95 7.42 0.37 5.06 7.67 0.53 7.93 5.05 1.46 
206 Platelet_homeostasis 6.09 9.24 8.54 4.65 2.39 2.06 2.09 4.92 4.99 1.75 0.36 0.61 6.47 6.18 0.13 7.27 7.12 8.96 
207 Nitric_oxide_stimulates_guanylate_cyclase 9.09 8.41 1.3 0.9 0.34 9.15 2.86 5.23 6.66 3.44 7.36 0.37 4.16 8.93 9.49 9.71 8.44 7.77 
208 Platelet_calcium_homeostasis 2.85 2 5.9 2.85 3.25 1.18 6.68 0.06 7.29 0.08 5.41 2.25 5.36 9.8 7.16 4.7 3.84 7.47 
209 Platelet_sensitization_by_LDL 3.28 9.36 2.04 7 5.23 3.64 4.11 0.4 2.5 5.04 4.83 7.66 1.41 6.7 8.45 5.06 0.88 2.56 
210 Prostacyclin_signalling_through_prostacyclin_receptor 1.07 2.66 8.57 6.78 1.99 6.74 1.55 1.91 9.9 8.32 8.58 9.96 9.17 2.9 9.67 7.07 2.34 2.46 
211 Class_I_MHC_mediated_antigen_processing_&amp;_presentation 4.62 4.02 2.39 4.26 0.95 9.06 3.14 3.5 5.86 2.79 7.76 8.22 8.79 3.01 8.12 6.76 1.64 3.57 
212 Costimulation_by_the_CD28_family 5.7 0.38 3.12 1.44 5.61 1.8 2 6.43 8.56 0.61 6.47 9.39 8.08 2.9 4.52 9.79 6.18 4.19 
213 Immunoregulatory_interactions_between_a_Lymphoid_and_a_non-Lymphoid_cell 0.07 2.84 5.47 9.77 6.75 6.13 7.09 3.71 6.42 3.39 3.36 6.21 5.01 0.34 1.29 3.58 4.36 4.69 
214 MHC_class_II_antigen_presentation 8.97 5.04 7.98 2.02 1.05 2.38 0.32 0.65 5.16 4.81 5.79 0.23 7.27 7.71 3.13 3.82 1.4 8.16 
215 Rap1_signalling 4.88 3.19 5.89 5.13 2.59 8.51 2.71 2.83 3.64 0.38 0.12 1.84 7.59 5.01 5.74 7.33 0.59 7.14 
216 Signaling_by_the_B_Cell_Receptor_(BCR) 6.49 5.95 5.22 5.41 4.16 3.77 0.52 5.65 8.91 1.38 3.1 9.67 0.55 7.87 2.24 2.22 4.39 4.41 
217 TCR_signaling 6.48 8.04 8.34 3.68 4.41 8.72 6.68 9.74 1.76 1.37 6.33 2.41 7.45 0.18 0.15 9.74 2.52 8.46 
218 Growth_hormone_receptor_signaling 9.56 5.24 9.66 5.81 1.44 2.4 3.34 2.96 8.76 0.27 2.05 0.18 2.91 6.41 4.65 1.91 4.71 2.59 
219 Interferon_Signaling 7 2.17 0.16 9.43 6.24 0.64 5.05 1.57 5.02 6.66 2.75 0.46 6.32 7.89 0.46 1.45 0.03 1.52 
220 Prolactin_receptor_signaling 9.01 3.26 1.53 1.84 6.49 3.5 4.05 3.46 0.25 9.7 3.36 7.95 7.93 3.23 5.32 8.56 8.96 2.1 
221 Signaling_by_Interleukins 7.76 6.92 5.5 2.9 7.95 8.52 3.5 3.15 0.36 3.61 7.6 9.84 7.29 5.34 0.5 0.82 8.06 9.36 
222 Advanced_glycosylation_endproduct_receptor_signaling 5.84 7.9 6.17 1.82 0.66 1.16 3.88 4.25 1.01 6.1 4.5 9.82 6.21 1.93 0.38 7.54 5.93 8.95 
223 Complement_cascade 2.8 6.38 1.67 4.2 3.45 8.83 8.65 6.96 8.33 3.9 6.32 1.89 8.39 1.83 8.17 1.29 7.53 6.79 
224 Cytosolic_sensors_of_pathogen-associated_DNA_ 6.13 6 2.52 1.45 8.61 1.51 3.18 9.63 8.13 9.07 5.54 4.76 6.17 2.11 4.29 2.64 9.66 5.31 
225 DAP12_interactions 9.42 6.98 5.22 1.55 5.87 2.57 1.58 4.64 7.62 5.1 9.46 0.65 3.8 1.65 9.46 5.4 2.97 0.42 
226 Defensins 4.64 1.94 5.84 2.7 7.15 2 2.06 1.06 3.02 6.96 8.33 6.11 0.67 4.15 6.45 1.75 3.54 4.48 
227 Fc_epsilon_receptor_(FCERI)_signaling 9.19 0.79 9.88 3.21 5.92 5.97 1.97 5.09 6.52 0.71 6.58 1.22 8.59 9.97 9.99 8.99 1.2 3.2 
228 Fcgamma_receptor_(FCGR)_dependent_phagocytosis 0.36 9.84 9.12 9.15 9.53 4.85 7.41 1.99 5.67 2.08 8.44 1.69 6.81 8.79 1.08 2.07 2.59 7.06 
229 Nucleotide-binding_domain,_leucine_rich_repeat_containing_receptor_(NLR)_signaling_pathways 8.49 0.75 0.26 1.24 6.07 7.74 8.84 1.28 5.46 1.45 4.81 7.14 1.49 1.68 3.38 3.07 7.93 5.04 
230 RIG-I/MDA5_mediated_induction_of_IFN-alpha/beta_pathways 1.05 6.97 2.17 9.55 6.41 3.43 1.33 0.97 6.79 7.36 5.55 6.33 9.54 9.3 2.52 9.04 2.79 4.88 
231 Toll-Like_Receptors_Cascades 8.7 7.54 0.72 1.76 7.01 4.15 0.86 2.31 4.8 9.75 2.6 5.14 9.38 6.57 9.9 4.38 9.81 4.47 
232 Ion_transport_by_P-type_ATPases 2.42 6.18 0.7 6.31 0.61 2.19 7.81 9.9 8.33 6.72 5.63 3.02 5.02 9.28 7.21 8.98 4.47 9.45 
233 Ligand-gated_ion_channel_transport 4.06 2.22 6.86 7.94 5.77 8.44 6.83 5.47 2.4 4.85 4.64 7.23 3.37 6.53 1.68 1.3 2.55 4.66 
234 Stimuli-sensing_channels 8.58 5.12 6.56 3.18 2.01 1.42 2.76 5.06 7.02 6.84 0.23 2.7 3.12 2.5 4.75 3.11 8.5 1.95 
235 TRP_channels 4.88 5.2 1.01 1.83 7.98 8.92 8.48 7.84 2.45 1.87 4.62 3.43 2.58 8.59 8.71 0.16 1.72 8.32 
236 Iron_uptake_and_transport 4.41 6.83 0.88 0.15 9.76 5.16 2.98 0.39 2.83 2.05 9.97 1.46 7.69 6.75 9.17 3.87 0.2 0.3 
237 Transferrin_endocytosis_and_recycling 4.42 7.35 3.89 3.73 4.8 0.73 7.77 7.86 3.81 7.85 5.22 3.45 9.79 0.85 7.13 9.35 7.35 8.83 
238 Meiotic_Recombination 1.86 0.96 6.48 0.85 7.52 5.21 2.6 9.82 6.36 6.88 9.19 2.36 7.92 0.65 2.78 1.98 4.96 3.86 
239 Meiotic_Synapsis 0.11 9.76 5.47 1.21 2.02 2.45 7.02 5.64 5.39 5.72 2.57 3.7 9.2 6.54 3.59 0.8 2.98 3.91 
240 COPII_(Coat_Protein_2)_Mediated_Vesicle_Transport 9.6 5.1 5.91 8.67 0.33 6.75 1.36 4.99 7.75 7.9 3.76 2.56 2.72 7.03 0.86 9.67 5.15 5.42 
241 Endosomal_Sorting_Complex_Required_For_Transport_(ESCRT) 4.95 5.66 4.56 1.86 4.37 1.98 6.26 3.64 0.85 6.65 9.08 3.4 3.6 8.14 1.54 0.12 7.52 3.38 
242 Gap_junction_trafficking 7.06 5.25 6.3 2.49 1.79 0.79 3.13 8.38 5.17 4.21 1.45 9.91 9.69 8.39 3.08 5.65 7.62 4.73 
243 Regulation_of_gap_junction_activity 6.81 9.7 1.47 0.53 7.08 5.08 7.15 4.29 0.66 6.89 6.63 7.71 5.41 2.59 6.31 5.72 5.14 9.66 
244 COPI_Mediated_Transport 9.88 1.7 1.68 1.99 6.55 8.5 4.44 9.36 2.78 4.06 4.27 3.13 5.23 3.71 3.27 0.73 4.61 1.73 
245 Translocation_of_GLUT4_to_the_Plasma_Membrane 9.34 1.02 5.87 4.17 4.63 1.53 1.26 5.95 4.95 2.13 4.06 3.7 8.59 3.05 4.96 8.33 2.23 8.52 
246 Clathrin_derived_vesicle_budding 8.79 5.19 1.26 7.93 5.85 4.65 3.71 4.44 1.07 2.71 0.87 0.99 5.19 5.96 7.15 5.52 4.92 7.53 
247 Abacavir_metabolism 2.57 5.9 9.59 3.57 8.86 8.09 8.65 6.86 0.19 2.59 3.13 4.35 0.28 1.01 4.68 8.69 4.56 7.31 
248 Abacavir_transmembrane_transport 5.78 0.74 3.95 8.43 2.74 3.16 0.24 5.11 5.85 7.22 9.71 0.57 0.95 1.74 0.38 1.83 6.58 2.95 
249 Phase_1_-_Functionalization_of_compounds 7.22 9.83 2.31 5.03 2.32 3 5.9 4.8 4.08 5.05 7.02 8.58 8.18 5.57 5.61 1.2 0.28 6.56 
250 Phase_II_conjugation 7.13 3.32 0.92 1.82 4.67 3.2 3.58 0.74 9.87 0.94 9.83 3.64 2.64 7.14 7.46 3.9 4.25 2.55 
251 Cytosolic_Iron-sulfur_Cluster_Assembly 1.63 4.67 7.92 2.31 6.19 8.8 7.18 1.28 9.48 7.2 0.79 0.91 7.66 5.87 8.08 1.26 8.25 1.59 
252 IP3_and_IP4_transport_between_cytosol_and_nucleus 5.18 2.2 0.35 3.14 4.56 1.47 1.56 1.34 3.6 7.51 2.08 4.78 2.94 5.89 5.24 9.76 6.94 0.9 
253 IP6_and_IP7_transport_between_cytosol_and_nucleus 1.89 3.72 4.19 3.01 7.02 8.44 5.23 5.39 6.09 8.27 6.37 1.86 4.16 8.27 1.69 6.23 8.99 5.14 
254 IPs_transport_between_ER_lumen_and_cytosol 4.15 6.44 4.36 6.69 3.78 6.76 8.58 9.52 8.46 1.37 9.15 9.88 6.16 2.88 3.82 0.74 3.33 9.15 
255 IPs_transport_between_ER_lumen_and_nucleus 0.56 6.56 0.62 6.16 5.24 1.29 4.42 9.84 8.72 0.49 3.96 0.26 5.82 2.02 7.75 4.16 6.65 5.52 
256 IPs_transport_between_cytosol_and_ER_lumen 7.59 7.55 4.17 8.44 5.54 4.43 8.24 9.99 4.22 1.21 7.33 4.13 9.17 7.93 8.73 0.6 1.75 0.74 
257 IPs_transport_between_nucleus_and_ER_lumen 9.85 5.01 6.22 2.08 3.95 0.26 7.2 2.91 9.88 9.29 0.72 9.77 1.93 0.08 2.54 9.22 8.76 1.37 
258 IPs_transport_between_nucleus_and_cytosol 8.16 8.03 0.9 9.12 2.89 2.53 9.79 2.99 3.22 9.02 6.02 3.69 6.54 7.29 7.34 4.38 2.74 2.26 
259 Synthesis_of_IP2,_IP,_and_Ins_in_the_cytosol 4.63 1.34 9.72 3.48 4.53 5.03 3.07 5.18 3.33 4.37 6.95 1.79 6.61 1.44 6.59 9.61 9.07 5.76 
260 Synthesis_of_IP3_and_IP4_in_the_cytosol 4.72 6.45 5.92 9.72 6.28 1.96 8.11 5.35 8.35 2.29 7.16 5.32 9.56 1.58 7.49 6.2 2.96 7.24 
261 Synthesis_of_IPs_in_the_ER_lumen 1.2 5.26 4.06 9.83 4.45 5.74 6.91 5.88 5.38 6.64 1.04 8.77 3.53 9.42 0.04 6.23 8.52 6.25 
262 Synthesis_of_IPs_in_the_nucleus 6.11 8.42 7.24 1.49 1.35 5.9 1.46 3.28 8.55 8.04 7.41 9.09 3.81 7.79 1.02 0.83 6.92 5.32 
263 Synthesis_of_pyrophosphates_in_the_cytosol 3.12 0.99 1.61 0.47 4.05 2.9 5.69 9.59 6.28 1.39 2.28 5.8 4.71 7.78 4.4 4.56 1.48 4.44 
264 Integration_of_energy_metabolism 7.45 1.25 2.1 6.98 6.16 1.8 8.15 0.64 2.26 4.72 4.79 5.93 4.82 0.05 5.36 3.33 1.05 5.87 
265 AMPK_inhibits_chREBP_transcriptional_activation_activity 7.32 6.38 1.65 0.64 5.18 3.99 0.32 5.08 8.96 4.38 9.78 6.38 2.45 0.59 1.69 7.44 3.62 7.69 
266 ChREBP_activates_metabolic_gene_expression 0.49 5.18 4.67 5.58 1.43 0.61 6.03 1.9 1.86 2.26 6.03 0.04 3 7.68 4.23 3.47 3.96 5.66 
267 Glucagon_signaling_in_metabolic_regulation 2.3 6.65 1.52 0 6.17 1.73 7.86 6.68 5.97 5.79 2.24 7.28 2.6 1.58 4.25 2.67 3.12 7.34 
268 Insulin_effects_increased_synthesis_of_Xylulose-5-Phosphate 4.52 1.69 5.62 5.7 2.11 2.35 8.9 7.11 0.64 7.5 9.6 5.45 7.67 7.54 7.87 2.17 5.65 9.42 
269 PKA-mediated_phosphorylation_of_key_metabolic_factors 0.88 2.73 8.15 5.79 8.37 3.88 2.69 8.86 8.3 8.09 6.4 3.21 3.19 8.81 6.26 0.2 4.11 4.54 
270 PP2A-mediated_dephosphorylation_of_key_metabolic_factors 8.93 9.84 3.57 9.99 3.36 8.29 9.5 4.57 4.05 3.65 3.34 0.49 0.94 5.92 2.7 1.19 0.17 3.13 
271 Regulation_of_Insulin_Secretion 2.53 1.17 9.77 1.6 5.05 1.53 5.91 5.62 5.76 8.54 0.72 1.34 0.16 0.5 1.93 9.45 8.52 7.47 
272 Amine-derived_hormones 5.21 0.61 3.44 2.59 3.66 8.85 4.39 7.18 1.07 2.68 5.54 0.5 4.32 7.99 0.2 7.35 0.98 7.92 
273 Amino_acid_synthesis_and_interconversion_(transamination) 9.16 1.82 0.29 3.16 0.59 7.58 5.83 3.99 1.35 3.57 0.7 2.71 3.42 7.8 8.77 4.06 2.95 6.86 
274 Branched-chain_amino_acid_catabolism 4.03 2.52 7.18 0.35 2.85 4.28 6.78 9.6 1.01 9.49 3.64 3.85 6.26 1.57 7.37 8.41 9.38 5.93 
275 Carnitine_synthesis 0.96 0.33 4.93 7.68 8.73 9.35 1.09 0.96 3.81 5.61 7.39 5.84 9.23 4.99 7.31 8.49 4.42 6.06 
276 Creatine_metabolism 8.5 2.87 0.4 7.69 2.23 5.88 4.67 0.83 4 1.58 6.06 9.38 4.63 9.2 3.66 7.58 6.85 0.23 
277 Glyoxylate_metabolism 2.29 2.98 3.56 4.7 1.75 1.96 6.83 9.88 6.19 9.46 1.9 2.75 4.69 5.19 3.41 1.97 5.45 6.54 
278 Histidine_catabolism 1.58 0.58 7.94 7.91 3.41 8.37 9 2.32 6.75 7.36 4.38 9.58 5.8 0.85 0.13 2.84 2.53 7.27 
279 Lysine_catabolism 2.85 4.26 6.7 5.36 2.81 3.7 5.49 3.48 0.77 1.99 8.35 5.73 1.37 3.51 7.31 6.17 2.33 5.71 
280 Metabolism_of_polyamines 3.76 5.29 7.31 0.44 3.42 4.67 0 5.28 9.16 6.34 9.99 7.57 2.4 5.81 6.23 9.41 1.31 7.49 
281 Phenylalanine_and_tyrosine_catabolism 5.39 2.99 5.75 0.99 3.63 2.45 7.26 2.01 4.24 0.83 3.89 7.35 0.24 8.95 7.45 1.7 4.83 7.17 
282 Proline_catabolism 3.92 7.52 3.24 7.73 7.4 2.55 4.68 0.7 8.43 0.3 7.56 7.65 1.14 9.8 4.58 3.58 1.24 0.08 
283 Regulation_of_ornithine_decarboxylase_(ODC) 3.11 6.67 7.17 9.28 5.9 0.99 5.8 8.7 9.9 4.12 0 0.64 2.75 0.84 6.82 9.11 1.06 8.68 
284 Sulfur_amino_acid_metabolism 6.44 8.26 4.36 3.66 5.92 9.88 8.38 8.65 2.12 9.47 4.46 6.59 0.52 7.71 2.56 1.1 0.57 6.66 
285 Tryptophan_catabolism 2.5 6.7 1.45 9.25 1.48 8.74 7.74 0.43 4.29 5.36 7.63 0.16 8.58 9.34 3.01 0.61 6.55 8.15 
286 Urea_cycle 1.74 5.82 1.39 0.82 0.24 9 5.75 3.37 3.76 3 4.24 8.64 5.37 6.95 5.25 6.29 8.51 7.88 
287 5-Phosphoribose_1-diphosphate_biosynthesis 7.94 7.44 7.06 0.75 0.71 4.9 8.84 8.19 9.79 1.95 1.58 8.07 8.45 3.74 4.38 1.56 8.2 4.32 
288 Digestion_of_dietary_carbohydrate 7.66 2.22 9.57 5.53 2.71 9.55 3.89 6.25 0.29 1.28 0.39 5.27 3.94 4.9 6.48 0.54 5.17 1.92 
289 Fructose_catabolism 5.3 6.18 1.48 0.56 9.9 2.82 7.43 4.39 3.01 4.93 9.27 2.69 3.93 0.33 4.31 5.92 1.35 0.26 
290 Galactose_catabolism 8.42 0.8 6.16 9.61 7.17 9.07 9.2 2.45 1.66 1.21 7.82 7.82 0.06 4.91 8.7 6.15 1.95 1.43 
291 Glucose_metabolism 7.63 7.71 5.92 9.35 2.17 4.12 8.81 4.67 7.21 9.52 3.22 8.28 2.3 4.29 4.24 6.99 1.53 1.51 
292 Glycosaminoglycan_metabolism 7.94 0.41 2.64 3.83 7.2 1.44 3.88 0.77 2.13 2.02 6.58 2.02 7.53 2.49 0.58 5.75 0.9 6.38 
293 Hexose_transport 8.23 3.95 7.01 2.05 5.58 1.23 2.87 0.41 0.26 5.3 2.09 8.2 9.35 0.43 5.31 6.74 9.02 1 
294 Pentose_phosphate_pathway_(hexose_monophosphate_shunt) 0.71 7.75 0.09 4.3 7.94 6.22 7.36 8.9 0.15 4.52 7.54 7.82 9.33 1.88 8.55 9.6 9.45 9.23 
295 Arachidonic_acid_metabolism 5.42 6.59 4.87 9.43 3.47 5.84 3.89 6.68 7.88 1.98 2.8 4.79 7.07 8.13 8.6 4.47 8.46 2.71 
296 Bile_acid_and_bile_salt_metabolism 1.82 3.44 1.42 4.48 6.36 3.53 5.49 8.88 8.23 8.25 2.51 1.9 6.39 0.46 3.62 7.75 6.24 0.78 
297 Cholesterol_biosynthesis 9.85 1.03 7.81 3.77 3.5 0.48 1.7 4.94 2.16 7.29 7.26 0.38 9.15 6.72 3.52 8.62 4.21 6.67 
298 Fatty_acid,_triacylglycerol,_and_ketone_body_metabolism 1.28 4.65 3.29 2.59 0.82 3.89 9.86 4.19 7.35 1.4 6.66 6.32 4.85 8.22 0.03 1.61 8.96 1.41 
299 Lipid_digestion,_mobilization,_and_transport 1.5 4.32 8.72 3.61 7.7 3.13 1.65 6.45 1.2 8.1 1.28 9.7 6.21 5.96 0.04 5.14 7.99 2.1 
300 Metabolism_of_steroid_hormones_and_vitamin_D 2.69 5.52 2.35 4.71 3.44 8.3 3.82 2.61 3.95 1.51 6.66 0.83 7.1 7.58 3.72 2.95 9.06 0.14 
301 Peroxisomal_lipid_metabolism 4.52 2.84 9.05 8.12 0.21 3.41 5.75 2.9 5.25 6.11 1.67 9.82 7.83 3.87 7.93 0.5 6.79 2.68 
302 Phospholipid_metabolism 2.74 8.84 6.29 3.35 4.6 1.05 5.11 9.92 8.24 5.5 0.16 0.6 8.01 7.59 3.09 9.23 0.67 3 
303 Regulation_of_Cholesterol_Biosynthesis_by_SREBP_(SREBF) 2.25 2.56 1.4 0.48 6.55 8.07 4.49 4.91 7.6 3.82 8.36 2.19 2.7 6.79 7.25 5.19 8.09 7.01 
304 Sphingolipid_metabolism 6.31 3.24 8.07 7.25 3.01 2.83 9.69 4.88 1.64 9.63 1.24 5.34 7.7 8.51 9.97 7.24 5.11 0.67 
305 Ubiquinol_biosynthesis 2.65 8.4 3.79 9.55 0.28 6.61 4.32 2.27 1.6 1.39 6.66 2.37 0.48 8.48 4.04 0.48 5.65 2.21 
306 alpha-linolenic_(omega3)_and_linoleic_(omega6)_acid_metabolism 1.33 1.75 2.41 5.14 1.47 3.62 9.54 6.76 4.54 6.58 7.21 7.84 6.88 4.66 1.16 8.56 1.8 4.29 
307 eNOS_activation_and_regulation 5.37 6.29 3.89 8.43 0.04 1.01 3.84 9.2 9.87 1.36 0.52 5.82 5.28 3.66 4.72 1.93 9.58 1.79 
308 Metabolism_of_nucleotides 9.83 9.87 8.23 3.97 0.96 5.94 9.01 6.53 5.2 5.03 4.72 0.2 9.32 9.53 8.24 0.33 0.57 6.65 
309 Phosphate_bond_hydrolysis_by_NUDT_proteins 7.32 2.8 1.67 9.66 6.9 8.68 9.26 8.28 4.79 1.44 7.03 4.49 8.33 0.03 9.1 2.4 0.27 6.1 
310 Purine_metabolism 5.27 2.82 3.93 1.87 8.63 9.61 5.65 5.99 2.51 3.18 0.81 5.58 1.03 3.58 2.38 1.78 4.64 4.57 
311 Pyrimidine_metabolism 5.72 2.21 9.22 7.56 8.67 2.6 2.98 3.43 2.34 8.41 0.19 3.52 0.62 4.11 8.11 7.93 4.05 8.81 
312 Synthesis_and_interconversion_of_nucleotide_di-_and_triphosphates 6.51 7.6 8.98 2.71 8.42 6.94 0.84 5.35 5 9.55 1.55 3.23 6.5 6.88 9.39 0.1 0.17 9.32 
313 Heme_biosynthesis 9.48 2.1 4.95 4.19 6.48 1.89 1.71 8.51 6.95 2.23 6.37 6.49 8 4.07 1.34 8.84 1.77 8.12 
314 Heme_degradation 6.41 3.04 4.96 1.62 5.37 5.51 8.51 7.32 5.65 9.38 4.45 2.28 1.94 5.26 1.78 7.45 9.28 2.05 
315 Metabolism_of_water-soluble_vitamins_and_cofactors 1.49 2.57 3.12 4.01 1.99 7.27 6.92 3.53 7.95 5.42 5.67 1.49 3.76 2.55 7.42 7.48 1.03 8.15 
316 Mitochondrial_Iron-Sulfur_Cluster_Biogenesis 0.47 0.73 9.65 7.49 1.37 1.69 3.31 9.7 0.53 7.68 0.52 1.78 1.56 9.81 6.95 5.86 9.29 7.31 
317 Electron_Transport_from_NADPH_to_Ferredoxin 2.78 8.59 7.52 0.89 9.58 2.38 0.54 9.72 2.08 6.56 1.71 1.47 5.03 5.11 1.74 8.19 1.07 2.05 
318 Uptake_of_Carbon_Dioxide_and_Release_of_Oxygen_by_Erythrocytes 5.99 7.88 2.61 0.45 4.35 4.92 7.32 0.76 6.67 4.03 3.67 8.99 0.54 1.67 2.12 1.14 1.29 7.93 
319 Uptake_of_Oxygen_and_Release_of_Carbon_Dioxide_by_Erythrocytes 9.77 8.54 0.12 8.31 8.89 3.26 6.47 2.99 4.89 6.74 8.36 6.12 3.87 9.57 5.03 4.91 4.82 8.29 
320 Reversible_Hydration_of_Carbon_Dioxide 0.27 3.61 9.52 4.96 6.46 1.83 5.97 5.54 0.32 1.02 9.45 4.76 2.24 0.81 1.95 6.23 6.32 3.43 
321 Pyruvate_metabolism_and_Citric_Acid_(TCA)_cycle 6.02 3.69 2.82 9.89 4.37 5.99 0.35 1.79 6.54 6.52 3.99 3.5 1.32 9.45 2.93 8.71 6.49 5.9 
322 Respiratory_electron_transport,_ATP_synthesis_by_chemiosmotic_coupling,_and_heat_production_by_uncoupling_proteins 2.04 1.77 7.05 3.19 7.5 5.28 2.28 7.22 6.68 7.85 7.74 1.84 6.51 8.84 0.37 9.15 1.89 6.81 
323 Mitochondrial_Protein_Import 0.74 7.59 8.5 5.46 2.6 4.27 2.33 4.21 1.61 8.18 5.46 3.5 2.63 4.61 8.46 4.58 5.94 3.71 
324 Incretin_Synthesis,_Secretion,_and_Inactivation 9.45 5.02 2.46 4.2 2.54 9.53 7.6 5.86 4.19 7.35 6.16 1.13 3.35 5.92 0.18 2.65 3.7 3.36 
325 Insulin_Processing 5.25 7.46 6.44 5.12 4.82 8.15 1.05 7.26 2.01 7.73 3.06 0.8 5.93 9.9 5.91 2.14 2.23 8.57 
326 Metabolism_of_Angiotensinogen_to_Angiotensins 7 8.49 3.22 2.85 7.62 7.02 2.68 3.74 1.52 8.48 2.35 6.38 7.62 2.37 2.72 7.92 2 3.43 
327 Peptide_hormone_biosynthesis 5.19 4.81 3.7 9.91 1.45 9.84 7.14 0.85 0.79 3.99 2.82 3.86 1.19 6.5 1.93 1.85 5.16 6.08 
328 Synthesis,_Secretion,_and_Deacylation_of_Ghrelin 8.88 4.99 4.25 8.96 7.69 3.31 8.14 5.02 9.7 5.37 5.98 0.77 3.98 8.51 8.88 4.63 0.53 5.05 
329 Asparagine_N-linked_glycosylation 7.41 2.67 6.62 6.55 0.81 6.95 6.18 8.72 0.94 6.7 5.38 1.21 4.45 5.23 2.43 3.65 7.18 1.35 
330 O-linked_glycosylation_of_mucins 9.37 5.99 4.99 1.92 5.54 1.24 0.31 0.66 4.29 7.22 5.56 8.18 8.75 6.92 9.1 3.61 1.32 7.28 
331 PTM:_gamma_carboxylation,_hypusine_formation_and_arylsulfatase_activation 5.22 1.49 2.77 8.26 3.48 2.78 7.77 3.38 1.75 9.44 1.25 1.39 8.21 3.4 6.4 9.66 0.81 1.48 
332 Post-translational_modification:_synthesis_of_GPI-anchored_proteins 5.47 9.51 9.07 5.51 1.1 5.57 0.77 0.09 4.03 5.76 5.4 0.23 5.74 4.54 3.69 9.06 4.85 9.99 
333 SUMOylation 0.48 9.3 5.73 6.58 8.16 8.84 3.73 0.31 6.04 7.83 7.91 4.22 0.1 9.87 3.64 5.68 9.94 5.79 
334 Chaperonin-mediated_protein_folding 0.23 7.09 6.57 1.41 2.85 4.77 0.23 2.72 8.28 4.35 5.49 5.17 0.09 7.43 8.67 2.65 5.9 8.91 
335 Post-chaperonin_tubulin_folding_pathway 3.69 5.38 6.04 7.76 2.12 9.91 6.93 4.09 6.2 1.97 6.62 1.28 1 7.59 8.42 4.4 0.89 4.94 
336 Regulation_of_Insulin-like_Growth_Factor_(IGF)_Transport_and_Uptake_by_Insulin-like_Growth_Factor_Binding_Proteins_(IGFBPs) 6.42 6.2 4.86 1.46 9.64 4.86 2.71 9.43 4.66 4.74 4.45 7.88 3.49 8.27 9.54 5.04 2.81 2.46 
337 Eukaryotic_Translation_Elongation 7.57 2.85 1.14 3.5 8.32 6.73 9.43 3.12 2.32 8.83 2.39 7.68 5.89 6.83 2.09 9.87 7.95 2.45 
338 Eukaryotic_Translation_Initiation 9.12 6.39 9.35 2.48 4.79 2.07 2.3 9.54 6.01 9.4 0.43 7.18 4.12 3.77 6.23 4.72 9.83 8.85 
339 Eukaryotic_Translation_Termination 6.86 7.2 2.57 7.02 4.39 6.06 2.76 9.24 6.52 0.37 0.35 6.99 3.16 8.9 3.67 6.06 2.21 9.75 
340 SRP-dependent_cotranslational_protein_targeting_to_membrane 5.2 7.92 5.65 5.47 2.58 6.84 5.31 8.29 7.82 7.05 1.62 6.89 9.23 8.7 3.42 2.82 1.96 1.8 
341 Activation_of_Chaperones_by_ATF6-alpha 9.69 0.72 7.15 0.51 7.36 7.55 1.74 4.77 1.54 7.29 8.82 8.51 7.69 2.37 3.01 6.76 6.04 0.73 
342 Activation_of_Chaperones_by_IRE1alpha 1.61 1.97 5.95 1.25 4.85 0.62 2.29 5.6 7.18 0.73 0.79 7.09 6.62 2.24 5.74 6.82 4.75 8.15 
343 PERK_regulated_gene_expression 3.43 4.46 5.32 5.68 6.84 3.61 4.72 2.86 2.66 0.89 1.51 6.04 2.33 5.94 0.76 5.98 6.04 5.33 
344 Smooth_Muscle_Contraction 4.68 1.84 4.17 9.64 6.16 0.14 0.66 9.96 8.73 1.48 5.1 3.96 9.41 7.91 8.66 5.89 0.2 3.55 
345 Striated_Muscle_Contraction 9.48 2.51 0.81 2.71 8.25 2.28 1.73 4.54 3.09 4.3 2.38 9.91 7.39 8.53 4.48 5.67 0.54 8.77 
346 Botulinum_neurotoxicity 4.9 1.97 0.56 7.73 5.89 8.62 5.36 4.29 8.88 5.39 5.85 8.41 1.67 5.2 5.6 0.47 5.81 3.82 
347 Proteolytic_cleavage_of_SNARE_complex_proteins 6.06 9.89 7.84 4.03 9.6 4.62 7.32 3.92 8.43 0.63 9.23 6.11 7.4 6.92 4.43 2.7 9.19 8.49 
348 Translocation_of_BoNT_Light_chain 1.12 5.76 8.45 4.86 5.56 6.03 3.64 4.98 5.08 8.78 3.38 7.23 0.05 4.11 1.93 1.17 9.43 2.27 
349 Ca2+_activated_K+_channels 5.14 2.9 4.16 8.01 3.39 5.44 2.36 0.12 2.74 4.33 7.4 4.01 1.83 1.35 8.28 6.33 4.37 1.34 
350 HCN_channels 5.77 6.71 7.22 2.63 6.59 5.4 3.68 2.82 8.48 3.66 2.9 2.27 4.58 0.71 1.06 3.05 0.01 4.34 
351 Inwardly_rectifying_K+_channels 7.7 5.55 5.07 2.99 7.3 0.75 8.03 4.39 1.94 4.88 6.64 6.73 0.48 3.58 2.8 4.87 7.64 7.13 
352 Tandem_pore_domain_potassium_channels 0.13 4.52 1.7 9.78 7.66 7.04 4.16 6.49 3.77 8.37 5.37 4.59 4.32 9.55 1.05 5.26 9.37 3.66 
353 Voltage_gated_Potassium_channels 9.14 1.55 2.9 4.46 1.82 6.35 0.93 9.36 8.46 2.38 4.56 4.03 7.14 5.99 0.41 9.25 0.74 3.24 
354 Depolarization_of_the_Presynaptic_Terminal_Triggers_the_Opening_of_Calcium_Channels 3.44 8.63 7.49 2.76 5.97 3.34 6.47 4.26 0.43 2.44 5.92 7.61 2.69 1.75 1.39 6.96 4.81 4.71 
355 Neurotransmitter_Clearance_In_The_Synaptic_Cleft 2.68 7.13 6.66 0.3 8.06 1.09 2.9 0.59 6.84 5.46 7.59 1.03 6.06 3.91 0.93 1.96 5.83 9.5 
356 Neurotransmitter_Receptor_Binding_And_Downstream_Transmission_In_The__Postsynaptic_Cell 5.57 4.35 0.12 6.67 8.69 1.65 9.03 9.73 7.91 5.16 1.49 5.15 1.18 2.43 3.88 4.97 7.11 0.91 
357 Neurotransmitter_Release_Cycle 8.74 5.63 1.25 0.07 3.7 1.21 7.27 6.58 3.36 2.75 2.21 5.76 7.99 9.19 2.41 6.11 7.12 2.09 
358 Neurotransmitter_uptake_and_Metabolism_In_Glial_Cells 6.35 2.63 8.3 5.14 3.36 7.83 0.32 9.88 3.39 7.05 6.7 9.4 8.68 3.91 7.28 9.85 5.37 3.2 
359 Electric_Transmission_Across_Gap_Junctions 1.24 9.97 3.54 7.03 4.94 5.62 8.65 5.54 7 3.02 7.14 6.29 7.94 0.26 4.63 5.28 7.48 6.79 
360 Conjugation_of_SUMO_to_E1_(UBA2:SAE1) 3.51 1.99 0.03 4.42 2.8 0.16 2.9 0.98 8.58 7.3 5.53 5.51 2.62 4.44 6.49 4.85 0.55 5.72 
361 Proteolytic_Processing_of_SUMO 8.89 8.58 5.52 1.29 6.4 8.6 0.46 6.27 0.44 4.22 9.36 4.73 1.54 3.33 7.56 0.51 3.91 5.34 
362 Transfer_of_SUMO_from_E1_to_E2_(UBE2I,_UBC9) 9.31 3.22 0.79 2.02 1.76 5.8 2.69 3.88 4.29 8.85 0.02 6.1 3.27 2.74 7.6 0.99 0.42 0.55 
363 Acrosome_Reaction 3.93 0.65 9.28 5.72 2.84 7.26 7.98 5.23 2.01 5.87 0.88 9.97 6.52 1.75 7.5 6.78 4.55 8.93 
364 Interaction_With_Cumulus_Cells 6.3 4.06 5.31 4.89 1.65 5.21 1.27 9.64 4.4 1.13 3.89 7.1 4.88 7.63 3.2 1.88 8.21 2.64 
365 Interaction_With_The_Zona_Pellucida 0.03 7.54 7.22 3.16 8.54 5.86 4.25 5.24 8.18 3.02 1.2 6.59 4.88 6.82 3.41 5.74 5 5.66 
366 Sperm_Motility_And_Taxes 2.22 7.54 5.52 8.5 5.16 2.26 4.86 6.02 7.37 9.01 9.01 7.49 9.67 1.02 2.65 8.81 8.43 7.1 
367 Sperm:Oocyte_Membrane_Binding 5.08 4.89 8.58 1.84 1.21 1.06 5.86 9.87 3.71 4.9 9.72 5.18 0.73 3.53 2.81 6.62 9.96 2.13 
368 Hexose_transport 4.51 1.15 8.04 7.85 3.33 5.64 5.04 8.37 4.53 7.84 3.33 9.72 9.21 5.44 3.7 2.57 0.88 1.29 
369 Glucose_transport 2.97 3.4 9.23 9.01 3.43 8.76 7.31 5 6.48 6.13 2.53 3.11 6.93 3.32 4.51 8.14 5.99 2.16 
370 Transport_of_glucose_and_other_sugars,_bile_salts_and_organic_acids,_metal_ions_and_amine_compounds 2.12 8.34 8.49 2.52 9.12 1.41 2.09 4.5 1.8 5.69 5.35 5.62 3.65 1.11 8.17 0.11 7.63 3.21 
371 Facilitative_Na+-independent_glucose_transporters 6.06 3.45 4.43 8.5 5.93 6.64 4.42 4.44 8.33 7.36 5.02 0.25 5.59 9.53 0.07 0.06 5.43 1.29 
372 Inositol_transporters 7.51 0.7 3.95 2.28 5.41 0.59 2.2 7.15 9.44 1.78 6.58 3.84 7.38 3.83 6.38 7.37 6.35 0.3 
373 Metal_ion_SLC_transporters 7.82 3.15 0.8 0.21 4.25 7.52 2.04 4.46 4.12 0.04 0.45 8.25 2.44 5.49 9.94 5.29 1.32 0.09 
374 Na+-dependent_glucose_transporters 3.16 4.29 7.61 1.33 9.3 7.46 5.32 2.83 8.73 4.39 8.8 8.35 9.87 5.7 5.89 6.29 5.6 5.21 
375 Na+/Cl-_dependent_neurotransmitter_transporters 5.97 1.89 1.63 4.44 6.21 7.05 8.15 7.13 3.34 9.99 1.37 6.15 1.64 0.58 5.11 3.83 8.46 9.43 
376 Organic_cation/anion/zwitterion_transport 7.37 8.31 6.55 2.51 3.51 2.9 0.52 2.95 4.2 0.61 3.6 7.67 2.73 0.34 1.33 1.91 3.01 3.78 
377 Proton-coupled_monocarboxylate_transport 3.87 8.79 5 6.15 7.09 0.72 0.61 9.52 9.7 8.23 0.64 5.37 0.5 6.1 7.91 9.78 4.43 1.61 
378 Rhesus_glycoproteins_mediate_ammonium_transport 8.21 7.18 2.98 1.83 9.33 6.95 7.09 0.72 4.68 7.03 8.64 8.45 8.49 0.5 6.46 1.42 4.44 1.55 
379 Sodium-coupled_sulphate,_di-_and_tri-carboxylate_transporters 4.59 7.68 8.85 3.01 7.68 8.47 6.06 1.87 5.35 3.09 3.64 6.33 3.51 1.4 6.25 7.24 3.46 2 
380 Transport_of_inorganic_cations/anions_and_amino_acids/oligopeptides 8.38 0.31 2.21 2.17 6.24 5.84 8.15 3.44 3.52 0.19 0.7 3.67 9.19 1.74 4.87 0.3 3.45 7.16 
381 Amino_acid_transport_across_the_plasma_membrane 0.44 6.99 1.62 6.85 1.15 3.21 5.02 5.41 8.04 5.73 7.33 4.52 8.11 2.29 2.24 1.59 9.83 6.65 
382 Bicarbonate_transporters 8.45 9.5 8.26 5.91 8.97 2.13 3.71 9.86 6.62 1.9 5.84 9.06 4.18 6.22 7.19 6.66 2.18 9.91 
383 Cation-coupled_Chloride_cotransporters 9.59 5.66 1.03 2.79 4.98 8.67 3.45 1.03 4.3 0.2 0.25 5.34 8.21 8.33 2.35 2.87 3.93 8.27 
384 Multifunctional_anion_exchangers 3.48 6.24 6.92 9.18 8 2.44 4.31 0.86 6.95 5.08 7.53 5.97 1.92 1.21 8.19 9.07 0.71 0.22 
385 Organic_anion_transporters 5.61 9.91 0.52 2.51 5.23 9.65 9.56 9.8 0.61 4.65 5.23 3 8.28 2.35 9.53 6.12 6.82 8.76 
386 Proton-coupled_neutral_amino_acid_transporters 1.57 2.89 2.92 1.99 7.76 4.61 8.42 1.31 6.6 7 6.38 0.8 6.2 5.45 9.29 1.68 1.41 7.62 
387 Proton/oligonucleotide_cotransporters 8.34 6.33 2.7 0.82 0 5.6 3.64 1.41 0.99 3.36 6.65 8.33 0.29 8.27 2.54 0.28 3.19 9.84 
388 Sodium-coupled_phosphate_cotransporters 1.1 1.68 4.17 3.97 1.25 4.06 4.1 4.63 0.48 6.9 9.69 3.44 5.99 6.43 1.55 4.64 5.37 5.58 
389 Sodium/Calcium_exchangers 2.06 9.11 4.14 9.47 2.93 1.29 5.87 0.8 0.85 7.64 2.34 0.76 0.15 1.18 3.84 8.47 6.48 5.47 
390 Sodium/Proton_exchangers 5.55 8.32 7.81 8.37 4.27 8.96 8.59 3.24 7.99 6.53 7.01 8.41 4.04 7.29 2.15 5.65 6.5 5.32 
391 Transport_of_vitamins,_nucleosides,_and_related_molecules 0.83 7.19 2.96 4.39 7.78 2.38 2.41 8.03 0.06 6.2 6.7 8.49 2.05 5.24 0.78 7.87 9.84 6.29 
392 Transport_of_fatty_acids 1.39 8.98 9.73 6.38 8.15 0.02 0.41 4.85 0.63 2.11 0.66 8.27 5.83 9.3 5.65 0.82 9.82 8.31 
393 Transport_of_nucleosides_and_free_purine_and_pyrimidine_bases_across_the_plasma_membrane 2.35 2.9 8.12 2.56 8.02 4.48 5.13 1.26 4.97 0.64 2.15 2.93 9.07 4.37 4.18 3.38 4.24 0.7 
394 Transport_of_nucleotide_sugars 1.83 3.45 3.28 0.59 4.83 2.21 5.37 5.6 3.49 9.23 8.83 9.05 8.47 3.13 7.86 9.84 4.09 2.34 
395 Transport_of_organic_anions 5 9.7 8.39 1.57 6.68 8.56 4.85 5.92 0.22 7.33 7.35 3.83 8.27 4.99 0.61 0.9 1.35 1 
396 Conjugation_of_SUMO_to_E1_(UBA2:SAE1) 4.79 5.73 9.06 8.85 2.45 2.09 8.36 9.81 9.39 6.99 1.01 4.07 1.95 2.19 0.84 4.27 3.55 5.6 
397 Proteolytic_Processing_of_SUMO 1.33 4.52 8 6.03 6.88 3.98 8.75 5.69 3.04 9.9 8.43 5.57 8.57 3.19 8.75 1.49 1.9 9.46 
398 Transfer_of_SUMO_from_E1_to_E2_(UBE2I,_UBC9) 7.98 4.67 3.46 5.09 0.8 4.79 9.81 2.07 7.19 1.38 4.25 6.99 7.7 0.14 5.1 3.55 2.32 7.65 
399 DAG_and_IP3_signaling 6.18 7.2 2.37 2.64 7.09 7.03 5.44 0.5 5.41 3.01 3.44 4.27 1.41 9.1 6.96 8.24 6.83 0.98 
400 CaM_pathway 6.4 1.31 5.7 7.54 5.35 9.03 4.45 6.09 4.14 0.32 9.17 6.3 3.18 4.32 4.13 0.9 4.61 1.32 
401 Integrin_alphaIIb_beta3_signaling 6.35 5.17 6.45 3.21 8.18 8.05 3.33 7.21 2.46 9.7 7.88 3.94 0.08 2.27 8.35 5.77 6.75 2.05 
402 GRB2:SOS_provides_linkage_to_MAPK_signaling_for_Intergrins_ 0.5 6.42 2.54 3.18 3.9 7.24 9.79 3.65 7.54 1.71 0.22 8.44 2.67 5.09 4.1 8.72 5.52 8.74 
403 p130Cas_linkage_to_MAPK_signaling_for_integrins 9.77 6.97 3.7 9.41 2.67 3.41 6.17 9.68 0.65 3.21 6.55 7.27 9.14 2.83 1.37 9.32 5.49 1.62 
404 PIP3_activates_AKT_signaling 8.82 0.35 5.92 1.35 9.3 5.34 5.2 7.28 6.88 7.24 6.34 2.33 6.03 1.25 1.22 7.82 7.6 0.65 
405 AKT_phosphorylates_targets_in_the_cytosol 9.3 2.64 4.23 3.22 4.86 9.08 6.38 6.31 5.65 4.26 3.62 5.63 3.78 4.19 8.51 7.41 3.15 0.76 
406 AKT_phosphorylates_targets_in_the_nucleus 1.68 5.21 0.98 5.87 5.31 2.39 3.39 5.52 8.3 4.74 7.81 7.42 1.18 9 7 2.34 6.06 6.8 
407 Negative_regulation_of_the_PI3K/AKT_network 7.9 9.23 3.99 1.68 4.85 6.34 4.55 5.44 4.44 7.08 8 2.19 5.18 3.49 9.47 5.8 2.99 4.48 
408 ERK_activation 6.84 1.19 1.32 3.4 8.88 7.7 2.97 4.33 1.4 6.22 5.45 5.4 7.27 2.5 0.82 2.47 0.99 0.5 
409 MEK_activation 7.3 3.96 3.04 3.31 8.05 0.51 0.82 1.39 7.67 3.7 6.76 1.43 5.56 9.73 1.16 9.57 2.86 3.66 
410 RAF_activation 4.33 8.43 6.72 8.14 2.98 4.71 9.37 2.61 8.09 9.2 5.86 3.27 4.41 0.53 3.23 5.28 4.91 5.97 
411 Signaling_by_Activin 0.99 8.81 8.23 3.1 6.71 5.78 9.93 0.9 6.53 2.34 2.66 2.47 1.13 4.22 7.45 9.74 4.88 0.22 
412 Antagonism_of_Activin_by_Follistatin 3.77 5.19 0.83 9.66 8.05 7.94 6.46 3.24 4.41 0.89 0.98 7.97 0.66 4.6 3.91 5.73 4.65 6.05 
413 Signaling_by_BMP 8.06 4.38 3.96 5.18 2.62 9.44 7.26 0.15 8.93 3.23 5.69 1.24 2.18 3.69 4.72 6.7 1.61 0.15 
414 Signaling_by_EGFR 8.25 7.29 4.94 0.37 1.95 8.3 5.49 3 7.01 7.94 5.61 3.03 9.92 9.59 9.48 2.06 6.13 9.69 
415 EGFR_downregulation 6.39 4.55 5.61 6.51 4.1 6.77 5.76 5.39 2.22 5.02 2.24 1.96 8.49 0.23 9.12 7.23 7.14 3.71 
416 EGFR_interacts_with_phospholipase_C-gamma 8.08 6.2 9.81 1.56 2.98 1.49 1.45 4.97 4.66 4.43 4.48 3.92 5.31 2.04 6.95 2.94 4.5 1.49 
417 GAB1_signalosome 9.51 5.81 5.98 8.45 6.75 2.45 5.84 4.33 1 3.99 5.67 2.97 0.09 9.41 2.31 0.99 8.98 9.74 
418 GRB2_events_in_EGFR_signaling 3.87 7.59 2.62 1.45 7.29 6.59 3.24 7.67 9.66 9.68 9.27 0.94 8.49 7.96 5.42 9.23 3.96 4.17 
419 SHC1_events_in_EGFR_signaling 4.11 3.68 0.48 7.81 8.33 5.74 6.88 8.84 6.68 4.68 4.25 2.04 8.44 9.21 9.6 9.11 9.22 9.51 
420 Signaling_by_ERBB2 7 3.42 6.3 4.25 4.3 4.51 7.2 1.98 5.27 4.8 4.05 3.82 4.25 6.14 6.12 2.04 1.92 0.09 
421 Downregulation_of_ERBB2:ERBB3_signaling 9.38 0.05 8.66 6.66 1.71 0.8 9.64 5.41 0.26 8.86 9.35 7.33 2.51 7.24 0.76 2.92 1.59 9.51 
422 GRB2_events_in_ERBB2_signaling 5.96 5.27 8.07 2.87 0.27 9.2 8.05 1.27 8.37 7.1 5.83 8.03 1.37 4.83 3.41 6.35 6.21 2.77 
423 GRB7_events_in_ERBB2_signaling 2.78 0.8 4.34 7.11 2.29 8.53 9.3 4.08 7.3 4.48 6.32 1.41 6.7 4.16 0.63 8.18 8.15 9.84 
424 PI3K_events_in_ERBB2_signaling 5.09 9.74 7.41 8.85 4.08 9.6 7.48 0.85 7.78 1.01 1.71 5.05 4.01 7.96 1.72 1.09 7.31 9.87 
425 PLCG1_events_in_ERBB2_signaling 6.7 5.25 1.84 8.02 7.27 7.46 6.88 3.52 1.97 9.89 8.95 3.98 9.51 0.18 3.73 2.57 7.19 8.73 
426 SHC1_events_in_ERBB2_signaling 9.15 0.68 8.83 6.1 8.59 1.25 5.96 8.39 5.83 5.18 1.59 5.18 0.61 1.67 6.03 1.66 9.38 2.26 
427 Signaling_by_ERBB4 1.93 8.82 8.76 7.6 7.38 5.57 7.8 5.54 0.78 0.61 8.68 5.21 6.73 0.98 7.57 2.58 4.19 3.45 
428 Downregulation_of_ERBB4_signaling 9.01 1.89 2.16 9.56 2.39 7.25 1.25 5.32 1.78 4.21 7.16 7.62 2.87 2.08 7.38 5.3 6.05 4.9 
429 Nuclear_signaling_by_ERBB4 7.99 5.69 4.07 2.53 4.13 6.56 7.85 5.83 3.48 5.93 7.99 3.62 6.06 6.66 7.35 2.19 6.71 6.64 
430 PI3K_events_in_ERBB4_signaling 5.99 6.08 8.47 0.14 9.14 2.12 5.07 6.22 3.27 4.92 3.2 9.99 8.98 2.71 3.86 1.92 5.52 2.17 
431 SHC1_events_in_ERBB4_signaling 5.24 9.88 6.93 0.89 6.88 4.14 2.96 2.68 3.46 3.58 7.37 7.45 5.68 7.97 8.25 6.47 2.21 2.37 
432 Signaling_by_FGFR 6.43 9.07 6.7 5.49 5.46 0.39 2.52 0.12 0.2 4.31 4.76 6.91 5.25 8.45 0.99 4.16 7.74 0.56 
433 Downstream_signaling_of_activated_FGFR 6.77 8.72 7.36 0.08 8.96 3.09 1.32 3.58 7.88 7.44 0.04 9.3 7.27 6.49 5.19 8.68 1.74 9.01 
434 FGFR_ligand_binding_and_activation 3.61 2.55 9.66 9.27 3.13 3.62 7.8 8.18 7.28 2.89 7.13 9.41 2.23 7.96 7.31 8.4 2.31 1.35 
435 Negative_regulation_of_FGFR_signaling 6.32 5.82 3.82 2.5 6.44 8.52 4.57 6.01 2.68 0.33 7.73 8.94 4.19 5.26 8.83 5.33 7.82 5.12 
436 GPCR_downstream_signaling 4.36 8.25 0.52 8.12 0.24 8.45 2.96 2.02 7.73 7.58 3.05 6.77 3.58 1.11 2.81 6.5 5.7 9.8 
437 GPCR_ligand_binding 2.53 3.27 3.59 7.16 7.97 1.18 7.18 7.77 3.81 0.65 1.52 7.13 3.71 1.76 5.86 8.74 2.42 2.41 
438 Gastrin-CREB_signalling_pathway_via_PKC_and_MAPK 5.09 0.97 6.62 2.48 2.42 1.48 5.92 5.36 6.2 6.17 2.29 6.24 7.81 6.38 7.06 5.61 3.5 5.47 
439 Opioid_Signalling 4.58 0.39 9.05 9.81 4.68 4.14 6.01 3.16 2.94 9.67 0.45 1.67 0.39 1.63 6 7.74 4.44 9.99 
440 Signaling_by_Hippo 5.25 0.8 2.17 8.24 4.49 0.86 6.74 2.57 1.85 2.15 0.58 2.75 2.3 5.82 2.11 0.37 2.7 9.62 
441 Signaling_by_Insulin_receptor 5.91 0.28 6.61 6.12 6.96 8.76 1 9.58 1.71 1.91 2.48 1.22 6.98 5.5 7.58 7.28 1.45 7.42 
442 Insulin_receptor_recycling 4.38 8.6 4.73 4.77 4.93 6.95 4.04 2.13 0.32 5.25 9.04 2.95 2.21 8.48 1.68 0.84 6.2 0.91 
443 Insulin_receptor_signalling_cascade 8.38 2.32 1.19 3.37 5.66 4.32 2.62 5.34 8.31 6.37 6.94 1.02 0.11 5.14 6.42 2.69 8.34 5.47 
444 Signaling_by_Leptin 7.3 5.03 0.41 6.06 4.11 2.97 7.37 1.02 0.15 0.63 1.17 3.17 9.99 1.51 6.43 5.38 7.82 4.54 
445 RAF/MAP_kinase_cascade 8.87 0.12 9.12 9.22 8.37 1.74 0.91 8.08 7.18 8.51 2.77 6.23 8.52 2.11 2.3 5.89 0.01 0.15 
446 Pre-NOTCH_Expression_and_Processing 4.87 7.28 0.29 9.21 9.87 8.63 3.27 4.88 4.77 7.14 8.46 4.75 0.82 8.31 8.39 6.19 1.69 6.47 
447 Signaling_by_NOTCH1 3.62 4.06 5.6 7.52 9.05 5.61 7.2 3.8 4.41 5.5 3.39 7.38 1.24 9.51 0.05 9.4 9.89 6.25 
448 Signaling_by_NOTCH2 4.82 1.04 6.53 3.8 4.3 6.11 6.06 0.58 7.87 0.51 3.27 4.3 6.22 7.47 4.07 2.96 7.14 2.05 
449 Signaling_by_NOTCH3 9.49 4.06 8.1 5.15 9.35 5.88 7.85 3.34 9.13 0.23 4.76 9.63 1.77 7.26 9.22 7.07 5.29 2.66 
450 Signaling_by_NOTCH4 6.27 4.25 9 2.48 9.75 5.3 7.57 4.13 0.96 0.16 0.92 9.05 2.51 8.07 7.3 7.03 5.47 4.52 
451 Signaling_by_PDGF 2.55 6.84 5.35 5.94 1.46 7.9 0.36 0.47 5.05 6.07 2.78 9.58 2.81 7.46 2.99 4.22 5.92 4.13 
452 Downstream_signal_transduction 8.08 0.52 0.41 7.91 5.76 9.24 6.57 7.08 9.46 9.58 6.32 2.63 6.27 8.31 4.41 6.79 6.37 1 
453 Rho_GTPase_cycle 6.37 9.09 7.5 6.54 5.4 5.97 8.27 9.79 0.46 1.39 8.38 0.81 8.98 7.92 2.21 6.97 2.93 8.13 
454 Signaling_by_SCF-KIT 2.06 9.29 6.93 3.51 8.16 1.94 2.38 9.88 6.75 9.71 4.21 9.8 6.83 9.66 0.99 7.56 6.09 4.66 
455 PIP3_activates_AKT_signaling 6.68 3.59 3.95 1.84 9.28 0.94 3.32 8.66 4.58 2.66 4.63 9.13 4.31 2.86 3.6 1.66 4.49 1.22 
456 RAF/MAP_kinase_cascade 2.6 8.83 1.73 9.66 7.06 9.46 4.74 7.08 3.46 6.7 8.2 2.66 0.69 3.78 9.27 0.38 8.84 3.59 
457 Regulation_of_KIT_signaling 7.67 9.78 0.3 9.21 1.91 8.9 0.93 4.44 8.09 5.07 0.4 5.23 2.22 6.47 1.5 2.25 2.62 3.82 
458 TGF-beta_receptor_signaling_activates_SMADs 9.69 7.4 0.01 8.55 3.05 5.26 2.87 8.63 9.79 9.66 4.78 3.45 2.09 8.86 9.06 7.2 6.43 6.06 
459 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 4.42 3.61 9.83 9.38 8.17 7.95 7.09 7.99 4.97 7.95 7.42 2.52 3.67 1.4 1.03 8.55 7.55 0.52 
460 Transcriptional_activity_of_SMAD2/SMAD3:SMAD4_heterotrimer 8.56 4.45 2.62 9.97 6.5 7.89 0.65 7.05 1.27 4.47 4.27 5.03 2.76 2.65 6.75 2.46 7.81 8.03 
461 Signaling_by_Type_1_Insulin-like_Growth_Factor_1_Receptor_(IGF1R) 8.15 2.63 7.6 3.16 5.81 7.77 5.33 8.28 7.84 7.03 4.44 4.76 3.74 1.08 5.35 4.02 9.35 4.41 
462 IGF1R_signaling_cascade 7.86 3.93 3.2 4.14 9.44 8.57 9.12 3.04 4.96 6.91 7.06 8.26 2.16 5.83 1.33 5.11 9.76 3.05 
463 VEGF_ligand-receptor_interactions 6.65 2.06 0.98 4.18 6.19 7.91 0.24 4.67 8.5 9.34 4.95 9.75 0.75 6.94 7.87 4.65 7.62 6.39 
464 Degradation_of_beta-catenin_by_the_destruction_complex 5.08 4.6 6.82 5.86 4.95 1.22 9.35 9.48 5.59 1.19 1.38 4.66 3.73 7.5 0.6 3.41 0.93 5.48 
465 WNT_ligand_biogenesis_and_trafficking 4.06 9.18 2.68 2.12 0.65 6.19 1.27 5.71 1.14 0.42 7.5 7.49 7.28 2.61 9.77 7.36 0.25 6.06 
466 NGF_processing 4.65 7.83 9.53 4.05 6.26 1.53 1.65 5.45 1.27 7.8 4.31 3.8 1.83 3.47 7.23 0.81 0.63 5.44 
467 NGF_signalling_via_TRKA_from_the_plasma_membrane 2.49 4.26 4.4 6.62 2.91 0.29 6.98 5.98 9.78 7.27 8.25 4.6 2.69 1.8 2.23 3.47 4.02 1.65 
468 p75_NTR_receptor-mediated_signalling 0.82 4.23 0.55 1.87 8.07 8.09 3.3 0.91 1.11 5.44 3.44 0.75 6.89 2.05 7.56 7.24 2.17 8.56 
469 Retinoid_metabolism_and_transport 0.48 7.6 2.8 6.5 0.88 9.66 0.67 7.78 1.73 8.43 0.48 9.32 5.76 7.63 5.98 3.35 6.16 8.57 
470 The_canonical_retinoid_cycle_in_rods_(twilight_vision) 9.8 1.66 6.61 4.91 9.33 9.29 0.85 2.5 8.91 6.93 2.88 2.88 7.86 0.57 5.59 8.27 9.1 2.26 
471 The_phototransduction_cascade 2.9 2.41 2.64 6.66 0.74 6.92 1.48 4.12 8.92 2.16 1.58 8.27 1.59 0.42 8.39 1.63 4.48 3.96 
472 The_retinoid_cycle_in_cones_(daylight_vision) 2.5 8.96 1.96 6.78 1.08 4.86 4.37 3.03 3.23 0.01 0.41 8.45 6.3 0.94 4 9.93 0.54 3.94 
473 ABC-family_proteins_mediated_transport 2.04 5.42 1.24 5.69 5.81 6.43 8.27 2.01 5.02 0.23 0.38 5.61 8.34 1.01 2.05 9 7.32 4.56 
474 ABCA_transporters_in_lipid_homeostasis 6.36 2.1 9.17 5.93 4.77 7.92 9.1 9.9 4.08 7.75 8.89 0.69 3.91 1.39 8.35 3.06 0.39 1.73 
475 Mitochondrial_ABC_transporters 0.69 5.73 4.44 8.27 1.95 3.36 3.95 1.02 3.16 0.07 0.22 7.64 9.48 0.08 7.72 0.08 7.9 1.57 
476 Passive_Transport_by_Aquaporins 0.47 8.31 0.86 6.96 9.06 4.67 8.14 1.9 4.67 6.05 5.11 3.83 6.53 4.39 8.26 9.42 9.29 4.4 
477 Regulation_of_Water_Balance_by_Renal_Aquaporins 5.27 5.4 8.86 4.43 0.47 1.53 4.7 6.1 6.05 7.09 9.71 4.71 2.42 3.32 8.42 4.2 2.25 8.81 
478 Transport_of_Glycerol_from_Adipocytes_to_the_Liver_by_Aquaporins 7.18 5.88 3.51 2.52 8.57 8.65 9.75 4.3 3.51 1.02 7.5 7.88 7.47 0.72 2.9 2.19 7.17 9.93 
479 Ion_transport_by_P-type_ATPases 7.6 7.56 0.92 6.93 1.99 0.32 8.49 8.73 3.43 9.33 4.44 8.56 4.86 0.25 3.64 0 3.32 0.22 
480 Ligand-gated_ion_channel_transport 1.45 0.53 7.09 8.95 7.47 5.08 3.19 6.34 1.36 1.23 2.44 9.82 4.9 3.75 5.46 4.39 0.48 5.65 
481 Stimuli-sensing_channels 9.62 1.68 7.19 4.69 9.82 1.13 2.87 3.4 7.66 6.33 2.9 3.21 6.36 6.77 9.95 9.06 4.63 2.49 
482 Iron_uptake_and_transport 6.2 0.56 1.33 5.66 9.55 0.57 4.21 4.61 5.01 6.6 9.16 1.63 7.38 3.78 3.97 3.34 5.88 4.99 
483 Transferrin_endocytosis_and_recycling 4.7 1.99 1.15 3.66 4.65 2.32 8.74 0.78 3.37 8 8.48 9.93 9.58 7.57 6.71 0.58 6.82 6.17 
484 Hexose_transport 0.65 7.06 8.2 3.12 2.04 6.02 1.97 1.36 6.43 1.16 9.78 3.06 6.24 1.15 4.73 1.6 6.78 3.36 
485 Transport_of_glucose_and_other_sugars,_bile_salts_and_organic_acids,_metal_ions_and_amine_compounds 7.19 6.08 1.88 7.82 3.21 6.16 2.23 7.12 1.86 1.7 7.66 0.42 2.68 4.58 8.76 6.62 9.46 9.81 
486 Transport_of_inorganic_cations/anions_and_amino_acids/oligopeptides 7.53 7.04 8.38 5.97 3.22 5.95 9.11 1.15 3.87 2.21 2.37 6.04 5.78 6.4 8.64 5.66 6.94 9.31 
487 Transport_of_vitamins,_nucleosides,_and_related_molecules 3.65 7.56 1.84 0.65 1.06 2.65 0 9.84 3.89 4.02 4.11 9.57 8.07 4.07 2.27 6.86 9.43 0.35 
